WO1995018799A1 - Phenyl heterocycles as cox-2 inhibitors - Google Patents

Phenyl heterocycles as cox-2 inhibitors Download PDF

Info

Publication number
WO1995018799A1
WO1995018799A1 PCT/CA1994/000688 CA9400688W WO9518799A1 WO 1995018799 A1 WO1995018799 A1 WO 1995018799A1 CA 9400688 W CA9400688 W CA 9400688W WO 9518799 A1 WO9518799 A1 WO 9518799A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
furanone
methylsulfonyl
fluorophenyl
bromo
Prior art date
Application number
PCT/CA1994/000688
Other languages
French (fr)
Inventor
Yves Ducharme
Jacques Yves Gauthier
Petpiboon Prasit
Yves Leblanc
Zhaoyin Wang
Serge Leger
Michel Therien
Original Assignee
Merck Frosst Canada Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/179,467 external-priority patent/US5474995A/en
Application filed by Merck Frosst Canada Inc. filed Critical Merck Frosst Canada Inc.
Priority to BR9408478A priority Critical patent/BR9408478A/en
Priority to JP7518234A priority patent/JP2788677B2/en
Priority to AU12694/95A priority patent/AU1269495A/en
Priority to EP95903727A priority patent/EP0739340A1/en
Publication of WO1995018799A1 publication Critical patent/WO1995018799A1/en
Priority to NO960393A priority patent/NO960393L/en
Priority to BG100350A priority patent/BG63082B1/en
Priority to FI962800A priority patent/FI108792B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • This invention relates to compounds and pharmaceutical compositions for the treatment of cyclooxygenase mediated diseases and methods of treatment thereof.
  • Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit hormone- induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Up until recently, only one form of cyclooxygenase had been
  • cyclooxygenase-1 cyclooxygenase-1 or the constitutive enzyme, as originally identified in bovine seminal vesicles.
  • cyclooxygenase-2 the gene for a second inducible form of cyclooxygenase (cyclooxygenase-2) has been cloned, sequenced and characterized from chicken, murine and human sources.
  • This enzyme is distinct from the cyclooxygenase-1 which has now also been cloned, sequenced and characterized from sheep, murine and human sources.
  • the second form of cyclooxygenase, cyclooxygenase-2 is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors.
  • cyclooxygenase-1 constitutive enzyme
  • cyclooxygenase-2 inducible form
  • cyclooxygenase-2 is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines.
  • a selective inhibitor of cyclooxygenase-2 will have similar
  • antiinflammatory, antipyretic and analgesic properties to a conventional non-steroidal antiinflammatory drug, and in addition would inhibit hormone-induced uterine contractions and have potential anti-cancer effects, but will have a diminished ability to induce some of the mechanism-based side effects.
  • such a compound should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.
  • the invention encompasses novel compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
  • the invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.
  • the invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases
  • X-Y-Z- is selected from the group consisting of:
  • R 1 is selected from the group consisting of:
  • R 2 is selected from the group consisting of:
  • heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one hetero atom which is S, O, or N, and optionally 1, 2, or 3 additionally N atoms; or
  • the heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2, 3, or 4 additional N atoms; said substituents are selected from the group consisting of:
  • halo including fluoro, chloro, bromo and iodo
  • R 3 is selected from the group consisting of:
  • substituent is C 1-3 alkyl
  • R 4 and R 4' are each independently selected from the group consisting of:
  • substituent is C 1-3 alkyl
  • R 5 , R 5 ', R 6 , R 7 and R 8 are each independently selected from the group consisting of:
  • R 5 and R 6 or R 7 and R 8 together with the carbon to which they are attached form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms;
  • Q is CO 2 H, CO 2 -C 1-4 alkyl, tetrazolyl-5-yl, C(R 7 )(R 8 )(OH), or
  • X-Y-Z- is selected from the group consisting of -C(O)-O-CR 5 (R 5' )- wwen side b is a double bond, and sides a and c are single bonds; and R 1 is selected from the group consisting of:
  • R 2 is selected from the group consisting of:
  • R 5 , R 5' and R 6 are each independently selected from the group consisting of:
  • R 5 and R 6 together with the carbon to which they are attached form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms.
  • alkyl is defined to include linear, branched, and cyclic structures, with C 1-6 alkyl including including methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • C 1-6 alkoxy is intended to include alkoxy groups of from 1 to 6 carbon atoms of a straight, branched, or cyclic
  • C 1-6 alkylthio is intended to include alkylthio groups of from 1 to 6 carbon atoms of a straight, branched or cyclic configuration.
  • Examples of lower alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc.
  • the propylthio group signifies -SCH 2 CH 2 CH 3 .
  • Heteroaryl includes furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,3-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,3,4-triazole, 1,2,5-oxadiazole, 1,2,5-thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,4,5-tetrazine, and the like.
  • Benzoheteroaryl includes the above heteroaryl rings to which it is possible to fuse a benzene ring.
  • Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers.
  • the present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved,
  • the invention encompasses pharmaceutical compositions for inhibiting cyclooxygenase and for treating cyclooxygenase mediated diseases as disclosed herein
  • the invention encompasses pharmaceutical compositions for inhibiting cyclooxygenase-2 and for treating cyclooxygenase-2 mediated diseases as disclosed herein
  • the invention encompasses a method of inhibiting cyclooxygenase and treating cyclooxygenase mediated diseases, advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 as disclosed herein comprising: administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I as disclosed herein.
  • a compound is said to selectively inhibit COX-2 in preference to COX-1 if the ratio of the IC50 concentration for COX-1 inhibition to COX-2 inhibition is 100 or greater.
  • compositions of the present invention comprise a compound of Formula I as an active ingredient or a
  • pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N--dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol,
  • ethanolamine ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine,
  • tripropylamine tripropylamine, tromethamine, and the like.
  • the Compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following surgical and dental procedures.
  • a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer.
  • Compounds of Formula I may also be useful for the treatment of dementia including pre-senile and senile dementia, and in particular, dementia associated with Alzheimer Disease (i.e., Alzheimer's dementia).
  • Compounds of Formula I will also inhibit prostanoidinduced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor and asthma.
  • NSAID'S particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems (including those relating to reduced or impaired platelet function); kidney disease (e.g., impaired renal function); those prior to surgery or taking anticoagulants; and those susceptable to NSAID induced asthma.
  • GI bleeding coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems (including those relating to reduced or impaired platelet function); kidney disease (e.g., impaired renal function); those prior to surgery or taking anticoagulants; and those susceptable to NSAID induced asthma.
  • compounds of Formula I will be useful as a partial or complete substitute for conventional NSAID'S in preparations wherein they are presently co-administered with other agents or
  • compositions for treating cyclooxygenase-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including
  • acetominophen or phenacetin a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a
  • decongestant including phenylephrine, phenylpropanolamine,
  • pseudophedrine oxymetazoline, ephinephrine, naphazoline
  • antutussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a diuretic; a sedating or non-sedating antihistamine.
  • the invention encompasses a method of treating
  • cyclooxygenase mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effect amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.
  • Compounds of the present invention are inhibitors of cyclooxygenase-2 and are thereby useful in the treatment of
  • cyclooxygenase-2 mediated diseases as enumerated above. This activity is illustrated by their ability to selectively inhibit cyclooxygenase-2 over cyclooxygenase-1. Accordingly, in one assay, the ability of the
  • PGE 2 (PGE 2 ) synthesized in the presence of arachidonic acid, cyclooxygenase- 1 or cyclooxygenase-2 and a compound of Formula I.
  • the IC 50 values represent the concentration of inhibitor required to return PGE 2 synthesis to 50% of that obtained as compared to the uninhibited control.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • warm-blooded animals such as mice, rats, horses, cattle sheep, dogs, cats, etc.
  • the compound of the invention is effective in the treatment of humans.
  • compositions for treating cyclooxygenase-2 mediated diseases as defined may optionally include one or more ingredients as listed above.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically
  • excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
  • an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions contain the active material in
  • excipients suitable for the manufacture of aqueous suspensions are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxy-propylmethy-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene sorbitan monooleate.
  • suspending agents for example sodium carboxymethyl-
  • the aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
  • preservatives for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • coloring agents for example ethyl, or n-propyl, p-hydroxybenzoate
  • flavoring agents such as sucrose, saccharin or aspartame.
  • sweetening agents such as sucrose, saccharin or aspartame.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
  • a dispersing or wetting agent e.g., talc, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol,
  • the pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions.
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxy-ethylene sorbitan monooleate.
  • the emulsions may also contain
  • sweetening and flavouring agents are sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol.
  • Suitable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • topical use creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
  • Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day.
  • inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition.
  • Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
  • the compounds of the present invention can be prepared according to the following methods.
  • the ⁇ -chlorovinylaldehyde III can be obtained from the ketone II and the Vilsmeier reagent (DMF-POCI 3 ) using the general method described by Weissenfels (Z Chem. 1966, 6, 471).
  • the thiophene compound IV is obtained from III using the general method described by Weissenfels (Z Chem. 1973, 13, 57).
  • the sulfonamide group (VI) can then be formed by the method of Kharash (J. Amer. Chem. Soc.
  • the thiophene IX can be prepared from ketone VIII.
  • Ketone X can be converted to the thiophene compound XI using general methods already described in Method A.
  • the other regioisomer XIV can be prepared from ketone XIII.
  • ketone II Bromination of ketone II gives the ⁇ -bromoketone XV which is then converted to the thiazole XVI after treatment with a thioamide. Similarly, ketone VIII can be converted to thiazole XVII.
  • Ketone XV can be converted to the imidazole compound XVIII after treatment with formamide using the preparation of Brederick et al, Chem. Ber. 1953, p. 88.
  • Pyrole compound XX can be obtained from diketone XIX using the general procedures of Friedman et al., J. Org. Chem. 1965, 30, p. 854, K. Dimroth et al., Ber. 1956, 56, 2602, K.Dimroth et al., Ann. 1961, 634, 102.
  • the free NH of the pyrole can be acylated with Cl-CO-lower alkyl in the presence of a base such as Et 3 N.
  • alkylated products can be prepared using alkyl halides as reagents with a base such as NaH.
  • the compounds of type XXV can be prepared from readily available 4-substituted phenylacetyl chlorides XXIa. Reaction of di(3-butenyl)cadmium with a 4-substituted phenylacetyl chloride provides ketone XXI. Ozonolysis of XXI affords keto aldehyde XXIb which is cyclized by base to give cyclopentenone XXII. Addition of
  • arylmagnesium bromide or aryllithium to XXII gives allylic alcohol XXIV.
  • 4-methylthiophenyllithium is used followed by oxidation with the magesium salt of monoperoxyphthalic acid (MMPP) or m-chloroperoxybenzoic acid (mCPBA) to introduce the required methylsulfonyl group in XXV.
  • MMPP monoperoxyphthalic acid
  • mCPBA m-chloroperoxybenzoic acid
  • Method G is the same as in Method F except R 1 containing acid chloride is used as starting material. R 2 is introduced at a later stage via a carbonyl addition reaction, followed by PCC oxidation.
  • the 4,5-disubstituted isothiazoles and isothiazol-3(2H)-one-1,1-dioxides can be prepared by the general method described by B. Schulze et al., Helvetica Chimica Acta, 1991, 74, 1059.
  • lactams XXXVII and XXXIX can be achieved by the same reaction as described in Method I, except an appropriate amide is used.
  • Methyl 2-hydroxy isobutyrate is silylated with TMSC1 to give the TMS ether XXXXI, which is treated with 4-methylthiophenyl-lithium to provide ketone XXXXII. Desilylation followed by acylation yields keto-ester XXXXIV, which can be cyclized to lactone XXXXV by base catalysis. Oxidation of XXXXV with MMPP or mCPBA affords the desired product XXXXVI.
  • XXXXIII is also described in U.S. 4,321,118 and Org. Coat. 1986, 6, 175-95.
  • the compound of Formula I can be tested using the following assays to determine their cyclooxygenase-2 inhibiting activity.
  • DIBAL diisobutylaluminum hydride
  • m-CPBA metachloroperbenzoic acid
  • MPPM monoperoxyphthalic acid, magnesium salt
  • NSAID non-steroidal anti-inflammatory drug
  • OXONE® 2KHSO 5 ⁇ KHSO 4 ⁇ K 2 SO 4
  • PCC pyridinium chlorochromate
  • PDC pyridinium dichromate
  • Ph phenyl
  • SAM aminosulfonyl or sulfonamide or SO 2 NH 2
  • TBAF tetra-n-butylammonium fluoride
  • TMS-CN trimethylsilyl cyanide
  • Step 2 Cis, trans-3-chloro-3-(4-fluorophenyl)-2-(4-(methylthio)phenyl)propenal
  • Step 4 5-(4-Ruorophenyl)-4-(4-(methylsulfinyl)phenyl)thiophene- 2-carboxylic acid methyl ester
  • Step 5 4-(4-(Aminosulfonyl)phenyl)-5-(4-fluorophenyl)thiophene- 2-carboxylic acid methyl ester
  • Step 6 3-(4-Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2- hydroxy-2-propyl)thiophene
  • Step 1 4-(4-(Aminosulfonyl)phenyl)-5-(4-fluorophenyl)thiophene- 2-carboxylic acid
  • Step 1 4-(2-(4-(Methylthio)phenyl)-1-oxo-ethyl)benzoic acid
  • Step 2 4-(1-Oxo-2-(4-(methylsulfonyl)phenyl)ethyl) benzoic acid methyl ester . :
  • Step 3 Cis,trans 4-(1-Chloro-3-oxo-2-(4-(methylsulfonyl)phenyl)- 1-propenyl)benzoic acid methyl ester
  • Step 4 5-(4-(Methoxycarbonyl)phenyl)-4-(4-(methylsulfonyl)phenyl)thiophene-2-carboxylic acid methyl ester
  • Step 5 5-(4-(Carboxyphenyl)-4-(4-(methylsulfonyl)phenyl)thiophene-2-carboxylic acid
  • Step 1 To 1-(4-Fluorophenyl)-2-(4-(methylthio)phenyl)ethanone of Example 1, Step 1 (17.9 g) in a solution of CH 2 Cl 2 -MeOH (272.0 mL/27.0 mL) at 0°C was added MPPM (28.0 g). The cooling bath was then removed and the reaction mixture stirred at r.t. for 1 h. At 0°C, additional MPPM (28.0 g) was added and the reaction mixture kept for 1.5 h at r.t. The insoluble material was filtered followed by evaporation of the solvents, the residue was then extracted with CH 2 Cl 2 -NaHCO 3 . After evaporation in vacuo, the resulting solid was washed with etherhexane (1:1) and filtered to provide the title compound 16.8 g.
  • Step 3 4-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)- thiazole
  • Step 4 1-(4-(Methylthio)phenyl)-2-(4-fluorophenyl)-2-cyclopenten-1-ol
  • Step 5 2-(4-Fluorophenyl)-3-(4-(methylthio)phenyl)-2-cyclopenten-1-one
  • Step 6 2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2- cyclopenten-1-one
  • Step 1 To the product of Step 1 (216 mg) dissolved in acetonitrile (4 mL) was added Et 3 N (0.26 mL), followed by 4-fluorophenylacetic acid (102 mg). After 1.5 h at room temperature 0.23 mL of DBU was added. The reaction mixture was stirred for another 45 min and then treated with 5 mL of 1N HCl. The product was extracted with EtOAc, dried over Na 2 SO 4 and concentrated. The residue was purified by flash chromatography (40% EtOAc in hexane) to yield 150 mg of the title compound as a solid.
  • Step 5 5,5-Dimethyl-3-(4-fluorophenyl-4-(4-(methylthio)phenyl)-2-
  • Step 6 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)- phenyl)-2-(5H)-furanone

Abstract

The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula (I).

Description

TITLE OF THE INVENTION
PHENYL HETEROCYCLES AS COX-2 INHIBITORS
BACKGROUND OF THE INVENTION
This invention relates to compounds and pharmaceutical compositions for the treatment of cyclooxygenase mediated diseases and methods of treatment thereof.
Non-steroidal, antiinflammatory drugs exert most of their antiinflammatory, analgesic and antipyretic activity and inhibit hormone- induced uterine contractions and certain types of cancer growth through inhibition of prostaglandin G/H synthase, also known as cyclooxygenase. Up until recently, only one form of cyclooxygenase had been
characterized, this corresponding to cyclooxygenase-1 or the constitutive enzyme, as originally identified in bovine seminal vesicles. Recently the gene for a second inducible form of cyclooxygenase (cyclooxygenase-2) has been cloned, sequenced and characterized from chicken, murine and human sources. This enzyme is distinct from the cyclooxygenase-1 which has now also been cloned, sequenced and characterized from sheep, murine and human sources. The second form of cyclooxygenase, cyclooxygenase-2, is rapidly and readily inducible by a number of agents including mitogens, endotoxin, hormones, cytokines and growth factors. As prostaglandins have both physiological and pathological roles, we have concluded that the constitutive enzyme, cyclooxygenase-1, is responsible, in large part, for endogenous basal release of prostaglandins and hence is important in their physiological functions such as the maintenance of gastrointestinal integrity and renal blood flow. In contrast, we have concluded that the inducible form, cyclooxygenase-2, is mainly responsible for the pathological effects of prostaglandins where rapid induction of the enzyme would occur in response to such agents as inflammatory agents, hormones, growth factors, and cytokines. Thus, a selective inhibitor of cyclooxygenase-2 will have similar
antiinflammatory, antipyretic and analgesic properties to a conventional non-steroidal antiinflammatory drug, and in addition would inhibit hormone-induced uterine contractions and have potential anti-cancer effects, but will have a diminished ability to induce some of the mechanism-based side effects. In particular, such a compound should have a reduced potential for gastrointestinal toxicity, a reduced potential for renal side effects, a reduced effect on bleeding times and possibly a lessened ability to induce asthma attacks in aspirin-sensitive asthmatic subjects.
SUMMARY OF THE INVENTION
The invention encompasses novel compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
Figure imgf000004_0001
The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.
DETAILED DESCRIPTION OF THE INVENTION
The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases
Figure imgf000005_0001
or pharmaceutically acceptable salts thereof wherein:
X-Y-Z-is selected from the group consisting of:
(a) -CH2CH2CH2-,
(b) -C(O)CH2CH2-,
(c) -CH2CH2C(O)-,
(d) -CR5(R5')-O-C(O)-,
(e) -C(O)-O-CR5(R5')-,
(f) -CH2-NR3-CH2-,
(g) -CR5(R5')-NR3-C(O)-,
(h) -CR4=CR4'-S-,
(i) -S-CR4=CR4'-,
(j) -S-N=CH-,
(k) -CH=N-S-,
(l) -N=CR4-O-,
(m) -O-CR4=N-,
(n) -N=CR4-NH-,
(o) -N=CR4-S-, and
(P) -S-CR4=N-;
(q) -C(O)-NR3-CR5(R5')-,
(r) -R3N-CH=CH-, provided R1is not -S(O)2Me,
(s) -CH=CH-NR3-, provided R1is not -S(O)2Me, when side b is a double bond, and sides a an c are single bonds; and X-Y-Z-is selected from the group consisting of:
(a) =CH-O-CH=, and
(b) =CH-NR3-CH=,
(c) =N-S-CH=,
(d) =CH-S-N=,
(e) =N-O-CH=,
(f) =CH-O-N=,
(g) =N-S-N=,
(h) =N-O-N=,
when sides a and c are double bonds and side b is a single bond;
R1 is selected from the group consisting of:
(a) S(O)2CH3,
(b) S(O)2NH2,
(c) S(O)2NHC(O)CF3,
(d) S(O)(NH)CH3,
(e) S(O)(NH)NH2,
(f) S(O)(NH)NHC(O)CF3,
(g) P(O)(CH3)OH, and
(h) P(O)(CH3)NH2,
R2 is selected from the group consisting of:
(a) C1-6alkyl,
(b) C3, C4, C5, C6, and C7, cycloalkyl,
(c) mono-, di- or tri-substituted phenyl or naphthyl wherein the substituent is selected from the group consisting of:
(1) hydrogen,
(2) halo,
(3) C1-6alkoxy,
(4) C1-6alkylthio,
(5) CN,
(6) CF3,
(7) C1-6alkyl,
(8) N3, (9) -CO2H,
(10) -CO2-C 1-4alkyl,
(11) -C(R5)(R6)-OH,
(12) -C(R5)(R6)-O-C1-4alkyl, and
(13) -C1-6alkyl-CO2-R5;
(d) mono-, di- or tri-substituted heteroaryl wherein the
heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one hetero atom which is S, O, or N, and optionally 1, 2, or 3 additionally N atoms; or
the heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2, 3, or 4 additional N atoms; said substituents are selected from the group consisting of:
(1) hydrogen,
(2) halo, including fluoro, chloro, bromo and iodo,
(3) C1-6alkyl,
(4) C1-6alkoxy,
(5) C1-6alkylthio,
(6) CN,
(7) CF3,
(8) N3,
(9) -C(R5)(R6)-OH, and
(10) -C(R5)(R6)-O-C1-4alkyl;
(e) benzoheteroaryl which includes the benzo fused analogs of (d);
R3 is selected from the group consisting of:
(a) hydrogen,
(b) CF3,
(c) CN,
(d) C1-6alkyl,
(e) hydroxyC1-6alkyl,
(f) -C(O)-C1-6alkyl,
(g) optionally substituted
(1) -C1-5 alkyl-Q, (2) -C1-3alkyl-O-C1-3alkyl-Q,
(3) -C1-3alkyl-S-C1-3alkyl-Q,
(4) -C1-5 alkyl-O-Q, or
(5) -C1-5 alkyl-S-Q,
wherein the substituent resides on the alkyl and the
substituent is C1-3alkyl;
(h) -Q;
R4 and R4' are each independently selected from the group consisting of:
(a) hydrogen,
(b) CF3,
(c) CN,
(d) C1-6alkyl,
(e) -Q,
(f) -O-Q;
(g) -S-Q, and
(h) optionally substituted
(1) -C1-5 alkyl-Q,
(2) -O-C1-5 alkyl-Q,
(3) -S.-C1-5 alkyl-Q,
(4) -C1-3alkyl-O-C1-3alkyl-Q,
(5) -C1-3alkyl-S-C1-3alkyl-Q,
(6) -C1-5 alkyl-O-Q,
(7) -C1-5 alkyl-S-Q,
wherein the substituent resides on the alkyl and the
substituent is C1-3alkyl, and
R5, R5', R6, R7 and R8 are each independently selected from the group consisting of:
(a) hydrogen,
(b) C1-6alkyl,
or R5 and R6 or R7 and R8 together with the carbon to which they are attached form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms; Q is CO2H, CO2-C 1-4alkyl, tetrazolyl-5-yl, C(R7)(R8)(OH), or
C(R7)(R8)(O-C 1-4alkyl); provided that when X-Y-Z is -S-CR4= CR4', then R4 and R4' are other than CF3 .
One Class within this embodiment are the compounds of Formula I
Figure imgf000009_0001
or pharmacetically acceptable salts thereof wherein:
X-Y-Z- is selected from the group consisting of -C(O)-O-CR5(R5')- wwen side b is a double bond, and sides a and c are single bonds; and R1 is selected from the group consisting of:
(a) S(O)2CH3,
(b) S(O)2NH2,
R2 is selected from the group consisting of:
(a) C1-6alkyl,
(b) C3, C4, C5, C6, and C7, cycloalkyl,
(c) heteroaryl,
(d) benzoheteroaryl,
(e) mono- or di-substituted phenyl wherein the substituent is selected from the group consisting of:
(1) hydrogen,
(2) halo,
(3) C1-6alkoxy,
(4) C1-6alkylthio,
(5) CN, (6) CF3,
(7) C1-6alkyl,
(8) N3,
(9) -CO2H,
(10) -CO2-C 1-4alkyl,
(11) -C(R5)(R6)-OH,
(12) -C(R5)(R6)-O-C1-4alkyl, and
(13) -C1-6alkyl-CO2-R5;
R5, R5' and R6 are each independently selected from the group consisting of:
(a) hydrogen,
(b) C1-6alkyl,
or R5 and R6 together with the carbon to which they are attached form a saturated monocyclic carbon ring of 3, 4, 5, 6 or 7 atoms.
For purposes of this specification alkyl is defined to include linear, branched, and cyclic structures, with C1-6alkyl including including methyl, ethyl, propyl, 2-propyl, s- and t-butyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Similarly, C1-6alkoxy is intended to include alkoxy groups of from 1 to 6 carbon atoms of a straight, branched, or cyclic
configuration. Examples of lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like. Likewise, C1-6alkylthio is intended to include alkylthio groups of from 1 to 6 carbon atoms of a straight, branched or cyclic configuration. Examples of lower alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies -SCH2CH2CH3.
Heteroaryl includes furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, 1,2,3-triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,3,4-triazole, 1,2,5-oxadiazole, 1,2,5-thiadiazole, pyridine, pyridazine, pyrimidine, pyrazine, 1,2,4-triazine, 1,3,5-triazine, 1,2,4,5-tetrazine, and the like.
Benzoheteroaryl includes the above heteroaryl rings to which it is possible to fuse a benzene ring.
Exemplifying the invention are:
(a) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2- hydroxy-2-propyl)thiophene,
(b) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene,
(c) 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2- propyl)thiophene,
(d) 3-(4-(Aminosulfonyl)phenyl)-2-cyclohexylthiophene,
(e) 5-(4-Carboxyphenyl)-4-(4-(methylsulfonyl)phenyl)thiophene-2-carboxylic acid,
(f) 4-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)thiazole,
(g) 2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2- cyclopenten-1-one
(h) 4-(4-(Methylsulfonyl)phenyl)-5-(4-fluorophenyl)isothiazole,
(i) 3-(4-Huorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)* furanone,
(j) 3-(4-Ruorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)- furanone,
(k) 3-(4-Ruorophenyl)-4-(4-(methylsulfonyl)phenyl)furan, (l) 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone,
(m) 2-(4-(Aminosulfonyl)phenyl)-3-(4-fluorophenyl)thiophene, and
(n) 3-(4-(Trifluoroacetylaminosulfonyl)phenyl)-2-(4- fluorophenyl)thiophene,
(o) 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(p) 5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone, (q) 5,5-Dimethyl-3-(3-chlorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone,
(r) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(s) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(t) 5,5-Dimethyl-3-(3,4-difluorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone,
(u) 5,5-Dimethyl-3-(3,4-dichlorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-fiιranone,
(v) 5,5-Dimethyl-3-(4-chlorophenyl)-4-(4-methylsulfonyl)phenyl)-2-(5H)-furanone,
(w) 3-(2-Naphyhyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)furanone,
(x) 5,5-Dimethyl-3-(2-naphyhyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(y) 3-phenyl-4-(4-(memylsulfonyl)phenyl)-2-(5H)-furanone.
Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such possible diastereomers as well as their racemic and resolved,
enantiomerically pure forms and pharmaceutically acceptable salts thereof.
Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers.
In a second embodiment, the invention encompasses pharmaceutical compositions for inhibiting cyclooxygenase and for treating cyclooxygenase mediated diseases as disclosed herein
comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above. Within this embodiment the invention encompasses pharmaceutical compositions for inhibiting cyclooxygenase-2 and for treating cyclooxygenase-2 mediated diseases as disclosed herein
comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula I as described above.
In a third embodiment, the invention encompasses a method of inhibiting cyclooxygenase and treating cyclooxygenase mediated diseases, advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 as disclosed herein comprising: administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I as disclosed herein.
For purposes of this specification a compound is said to selectively inhibit COX-2 in preference to COX-1 if the ratio of the IC50 concentration for COX-1 inhibition to COX-2 inhibition is 100 or greater.
The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a
pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N--dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol,
ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine,
tripropylamine, tromethamine, and the like.
It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.
The Compound of Formula I is useful for the relief of pain, fever and inflammation of a variety of conditions including rheumatic fever, symptoms associated with influenza or other viral infections, common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, injuries, following surgical and dental procedures. In addition, such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer. Compounds of Formula I may also be useful for the treatment of dementia including pre-senile and senile dementia, and in particular, dementia associated with Alzheimer Disease (i.e., Alzheimer's dementia).
Compounds of Formula I will also inhibit prostanoidinduced smooth muscle contraction by preventing the synthesis of contractile prostanoids and hence may be of use in the treatment of dysmenorrhea, premature labor and asthma.
By virtue of its high cyclooxygenase-2 (COX-2) activity and/or its selectivity for cyclooxygenase-2 over cyclooxygenase- 1 (COX- 1) as defined above, compounds of Formula I will prove useful as an alternative to conventional non-steroidal antiinflammatory drugs
(NSAID'S) particularly where such non-steroidal antiinflammatory drugs may be contra-indicated such as in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; GI bleeding, coagulation disorders including anemia such as hypoprothrombinemia, haemophilia or other bleeding problems (including those relating to reduced or impaired platelet function); kidney disease (e.g., impaired renal function); those prior to surgery or taking anticoagulants; and those susceptable to NSAID induced asthma.
Similarly, compounds of Formula I, will be useful as a partial or complete substitute for conventional NSAID'S in preparations wherein they are presently co-administered with other agents or
ingredients. Thus in further aspects, the invention encompasses
pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined above comprising a non-toxic therapeutically effective amount of the compound of Formula I as defined above and one or more ingredients such as another pain reliever including
acetominophen or phenacetin; a potentiator including caffeine; an H2-antagonist, aluminum or magnesium hydroxide, simethicone, a
decongestant including phenylephrine, phenylpropanolamine,
pseudophedrine, oxymetazoline, ephinephrine, naphazoline,
xylometazoline, propylhexedrine, or levo-desoxyephedrine; an
antutussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; a diuretic; a sedating or non-sedating antihistamine. In addition the invention encompasses a method of treating
cyclooxygenase mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effect amount of the compound of Formula I, optionally co-administered with one or more of such ingredients as listed immediately above.
Compounds of the present invention are inhibitors of cyclooxygenase-2 and are thereby useful in the treatment of
cyclooxygenase-2 mediated diseases as enumerated above. This activity is illustrated by their ability to selectively inhibit cyclooxygenase-2 over cyclooxygenase-1. Accordingly, in one assay, the ability of the
compounds of this invention to treat cyclooxygenase mediated diseases can be demonstrated by measuring the amount of prostaglandin E2
(PGE2) synthesized in the presence of arachidonic acid, cyclooxygenase- 1 or cyclooxygenase-2 and a compound of Formula I. The IC50 values represent the concentration of inhibitor required to return PGE2 synthesis to 50% of that obtained as compared to the uninhibited control.
Illustrating this aspect, we have found that the Compounds of the Examples are more than 100 times more effective in inhibiting COX-2 than they are at inhibiting COX-1. In addition they all have a COX-2 IC50 of 1 nM to 1 μM. By way of comparison, Ibuprofen has an IC50 for COX-2 of 1 μM, and Indomethacin has an IC50 for COX-2 of approximately 100 nM. For the treatment of any of these cyclooxygenase mediated diseases, compounds of Formula I may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.
As indicated above, pharmaceutical compositions for treating cyclooxygenase-2 mediated diseases as defined may optionally include one or more ingredients as listed above.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically
acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the
gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108; 4,166,452; and
4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in
admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethyl-cellulose, methylcellulose, hydroxy-propylmethy-cellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example, lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example, polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example, arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example, beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, sweetening, flavoring and coloring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of an oil-in-water emulsions. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example, liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example, soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example, polyoxy-ethylene sorbitan monooleate. The emulsions may also contain
sweetening and flavouring agents.
Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents. The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
Compounds of Formula I may also be administered in the form of a suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compound of Formula I are employed. (For purposes of this application, topical application shall include mouth washes and gargles.)
Dosage levels of the order of from about 0.01 mg to about 140 mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5 mg to about 7 g per patient per day. For example, inflammation may be effectively treated by the administration of from about 0.01 to 50 mg of the compound per kilogram of body weight per day, or alternatively about 0.5 mg to about 3.5 g per patient per day.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.
It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. Methods of Synthesis
The compounds of the present invention can be prepared according to the following methods.
Method A:
The β-chlorovinylaldehyde III can be obtained from the ketone II and the Vilsmeier reagent (DMF-POCI3) using the general method described by Weissenfels (Z Chem. 1966, 6, 471). The thiophene compound IV is obtained from III using the general method described by Weissenfels (Z Chem. 1973, 13, 57). The thiol compound V can be obtained after oxidation of compound IV (Ra = -SMe) with one equivalent of m-CPB A followed by treatment of the resulting sulfoxide with TFAA at reflux. The sulfonamide group (VI) can then be formed by the method of Kharash (J. Amer. Chem. Soc. 1951, 73, 3240). The hydrolysis of compound VI and decarboxylation with Cu bronze in quinoline provides compound VII. Compound VII (R4 = H) can be treated with halogenating agent such as bromine in acetic acid to allow the preparation of the 5-bromothiophene (VII, R4 = Br). When it is desired to have a nitrile group at C-5, this can be accomplished from VI via amide formation using the Weinreb methodology {Tetrahedron Letters, 1977, 4171) followed by dehydration with TFAA. The CF3 group can be introduced at C-5 of VII via the method of Girard (J. Org. Chem. 1983, 48, 3220).
The introduction of an alkyl group at C-5 can be achieved via a Friedel-Crafts reaction on VII (R4 = H) and an acyl chloride, Cl- CO-lower alkyl and a catalyst such as TiCI4, followed by reduction. For R4=Me, this can be achieved from the ester (R4=CO2Me) via a DIBALr H reduction followed by deoxygenation using the method of Lau (J. Org. Chem. 1986, 51, 3038). Tertiary alcohols (R4= - C(CH3)2OH) can be obtained from VI and MeMgBr. These tertiary alcohols can also be deoxygenated using the method of Lau. Similarly, the thiophene IX can be prepared from ketone VIII.
Figure imgf000021_0001
Figure imgf000022_0001
Method B:
Ketone X can be converted to the thiophene compound XI using general methods already described in Method A. The thiophene XII can be prepared by metallation of XI with n-BuLi, quenching with methyl phosphonic dichloride and addition of water or ammonia (X' = OH or NH2). Similarly, the other regioisomer XIV can be prepared from ketone XIII.
Figure imgf000023_0001
Method C:
Bromination of ketone II gives the α-bromoketone XV which is then converted to the thiazole XVI after treatment with a thioamide. Similarly, ketone VIII can be converted to thiazole XVII.
Figure imgf000024_0001
Method D:
Ketone XV can be converted to the imidazole compound XVIII after treatment with formamide using the preparation of Brederick et al, Chem. Ber. 1953, p. 88.
Figure imgf000025_0001
Method E:
Pyrole compound XX can be obtained from diketone XIX using the general procedures of Friedman et al., J. Org. Chem. 1965, 30, p. 854, K. Dimroth et al., Ber. 1956, 56, 2602, K.Dimroth et al., Ann. 1961, 634, 102. The free NH of the pyrole can be acylated with Cl-CO-lower alkyl in the presence of a base such as Et3N. Also alkylated products can be prepared using alkyl halides as reagents with a base such as NaH.
Figure imgf000025_0002
Method F:
The compounds of type XXV can be prepared from readily available 4-substituted phenylacetyl chlorides XXIa. Reaction of di(3-butenyl)cadmium with a 4-substituted phenylacetyl chloride provides ketone XXI. Ozonolysis of XXI affords keto aldehyde XXIb which is cyclized by base to give cyclopentenone XXII. Addition of
arylmagnesium bromide or aryllithium to XXII gives allylic alcohol XXIV. Oxidation of XXIV with pyridinium chlorochromate affords the desired 2,3-disubstituted cyclopentenone XXV. For preparation of compound XXV (R1=SO2Me), 4-methylthiophenyllithium is used followed by oxidation with the magesium salt of monoperoxyphthalic acid (MMPP) or m-chloroperoxybenzoic acid (mCPBA) to introduce the required methylsulfonyl group in XXV.
Figure imgf000027_0001
Method G:
The sequence of Method G is the same as in Method F except R1 containing acid chloride is used as starting material. R2 is introduced at a later stage via a carbonyl addition reaction, followed by PCC oxidation.
Figure imgf000028_0001
Method H:
The 4,5-disubstituted isothiazoles and isothiazol-3(2H)-one-1,1-dioxides can be prepared by the general method described by B. Schulze et al., Helvetica Chimica Acta, 1991, 74, 1059. Thus, aldehyde III (Ra=SO2Me) or XXVII is treated with excess NH4SCN in refluxing acetone to proyide the corresponding 4,5-disubstituted isothiazoles XXX and XXVIII, oxidation of which with hydrogen peroxide yields XXXI and XXIX.
Figure imgf000029_0001
Method I:
An appropriately substituted aryl bromomethyl ketone is reacted with an appropriately substituted aryl acetic acid in a solvent such as acetonitrile in the presence of a base such as triethylamine and then treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) to afford either the lactone XXXIII or XXXV.
Figure imgf000030_0001
Method J:
Either of the lactones XXXIII or XXXV in a solvent such as THF is reacted with a reducing agent such as diisobutyl aluminium hydride or lithium borohydride at -78°C, to yield the furan XXXVI.
Figure imgf000031_0001
Method K:
The preparation of lactams XXXVII and XXXIX can be achieved by the same reaction as described in Method I, except an appropriate amide is used.
Figure imgf000032_0001
Method L:
Methyl 2-hydroxy isobutyrate is silylated with TMSC1 to give the TMS ether XXXXI, which is treated with 4-methylthiophenyl-lithium to provide ketone XXXXII. Desilylation followed by acylation yields keto-ester XXXXIV, which can be cyclized to lactone XXXXV by base catalysis. Oxidation of XXXXV with MMPP or mCPBA affords the desired product XXXXVI.
Figure imgf000033_0001
Figure imgf000034_0001
An alternative preparation of the hydroxy ketone XXXXIII is the oxidation of the known (J. Org. Chem. 1991 56, 5955-8; Sulfur Lett. 1991, 12, 123-32) ketone XXXXIV. A mixture of XXXXIV, aquous base, such as NaOH, organic solvents such as carbon
tetrachloride/toluene and a phase transfer catalyst such as ALIQU AT 336 is stirred in air at room temperature to provide XXXXIII. Compound XXXXIII is also described in U.S. 4,321,118 and Org. Coat. 1986, 6, 175-95.
Representative Compounds
Tables I and II illustrate compounds of Formula I.
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
10
15
20
25
30
Figure imgf000058_0001
Figure imgf000059_0001
Assays for Determining Biological Activity
The compound of Formula I can be tested using the following assays to determine their cyclooxygenase-2 inhibiting activity.
Inhibition of Cyclooxygenase Activity
Compounds were tested as inhibitors of cyclooxygenase activity in whole cell and microsomal cyclooxygenase assays. Both of these assays measured prostaglandin E2 (PGE2) synthesis in response to arachidonic acid, using a radioimmunoassay. Cells used for whole cell assays, and from which microsomes were prepared for microsomal assays, were human osteosarcoma 143 cells (which specifically express cyclooxygenase-2) and human U-937 cells (which specifically express cyclooxygenase-1). In these assays, 100% activity is defined as the difference between prostaglandin E2 synthesis in the absence and presence of arachidonate addition. IC50 values represent the
concentration of putative inhibitor required to return PGE2 synthesis to 50% of that obtained as compared to the uninhibited control.
Representative results are shown in Table III.
Representative Rat Paw Edema Assay - Protocol
Male Sprague-Dawley rats (150-200 g) were fasted overnight and were given po either vehicle (5% tween 80 or 1%
methocel) or a test compound at 9 - 10 am. One hr later, a line was drawn using a permanent marker at the level above the ankle in one hind paw to define the area of the paw to be monitored. The paw volume (VOh) was measured using a plethysmometer (Ugo-Basile, Italy) based on the principle of water displacement. The animals were then injected subplantarly with 50 ul of a 1% carrageenan solution in saline (FMC Corp, Maine) into the paw using an insulin syringe with a 25-gauge needle (i.e. 500 ug carrageenan per paw). Three hr later, the paw volume (V3h) was measured and the increases in paw volume (V3h - VOh) were calculated. The animals were euthanized by CO2 aphyxiation and the absence or presence of stomach lesions scored. Stomach scores were expressed as the sum of total lesions in mm. Paw edema data were compared with the vehicle-control group and percent inhibition
calculated taking the values in the control group as 100%. Since a maximum of 60 - 70% inhibition (paw edema) was obtained with standard NSAIDs, ED30 values were used for comparison. All treatment groups were coded to eliminate observer bias. With this protocol, the ED30 for Indomethacin is 1.0 mg/kg. Representative results are shown in Table IV.
Figure imgf000061_0001
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000074_0001
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001
Figure imgf000080_0001
The invention will now be illustrated by the following non- limiting examples in which, unless stated otherwise:
(i) all operations were carried out at room or ambient
temperature, that is, at a temperature in the range 18-25°C; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm Hg) with a bath temperature of up to 60°C; the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only; melting points are uncorrected and 'd' indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with different melting points in some preparations; the structure and purity of all final products were assured by at least one of the following techniques: TLC, mass spectrometry, nuclear magnetic resonance (NMR) spectrometry or microanalytical data; yields are given for illustration only; when given, NMR data is in the form of delta (δ) values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 300 MHz or 400 MHz using the indicated solvent;
conventional abbreviations used for signal shape are: s. singlet; d.
doublet; t. triplet; m. multiplet; br. broad; etc.: in addition "Ar" signifies an aromatic signal; chemical symbols have their usual meanings; the following abbreviations have also been used v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg (milligrams(s)), mol (moles), mmol (millimoles), eq (equivalent(s)).
The following abbreviations have the indicated meanings:
Ac = acetyl
Bn = benzyl
DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene
DIBAL = diisobutylaluminum hydride
DMAP = 4-(dimethylamino)pyridine
DMF = N,N-dimethylformamide
Et3N = triethylamine
LDA = lithium diisopropylamide
m-CPBA = metachloroperbenzoic acid
MMPP = monoperoxyphtalic acid
MPPM = monoperoxyphthalic acid, magnesium salt
6H2O
Ms = methanesulfonyl = mesyl = SO2Me
Ms0 = methanesulfonate = mesylate
NSAID = non-steroidal anti-inflammatory drug
OXONE® = 2KHSO5·KHSO4·K2SO4
PCC = pyridinium chlorochromate PDC = pyridinium dichromate
Ph = phenyl
Phe = benzenediyl
Pye = pyridinediyl
r.t. = room temperature
rac. = racemic
SAM = aminosulfonyl or sulfonamide or SO2NH2
TBAF = tetra-n-butylammonium fluoride
Th = 2- or 3-thienyl
TFAA = trifluoroacetic acid anhydride
THF = tetrahydrofuran
Thi = thiophenediyl
TLC = thin layer chromatography
TMS-CN = trimethylsilyl cyanide
Tz = 1H (or 2H)-tetrazol-5-yl
C3H5 allyl
Alkyl Group Abbreviations
Me = methyl
Et = ethyl
n-Pr = normal propyl
i-Pr = isopropyl
n-Bu = normal butyl
i-Bu = isobutyl
s-Bu = secondary butyl
t-Bu = tertiary butyl
c-Pr = cyclopropyl
c-Bu = cyclobutyl
c-Pen = cyclopentyl
c-Hex = cyclohexyl EXAMPLE 1
3-(4-Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-hydroxy-2-propyl)thiophene
Step 1: 1-(4-Fluorophenyl)-2-(4-(methylthio)phenyl)ethanone
To 4-fluorobenzaldehyde (5.40 g) in 1,2-dichloroethane (43.50 mL) were added TMS-CN (4.32 g) and ZnI2 (44 mg). After 0.5 h at r.t., the solvent was removed in vacuo. To the resulting TMS cyanohydrin (9.20 g) in THF (42.0 mL) at -78°C was added dropwise a solution of LDA 0.51M in THF (88.9 mL). After a period of 0.5 h, a THF solution (30.0 mL) of 4-(chloromethyl)thioanisole (9.93 g) was added dropwise over 0.5 h. After 18 h at +5°C, the resulting mixture was treated with TBAF (57.5 mL) followed by a 25% aqueous solution of NH4OAc (100 mL) and extracted with EtOAc (2 × 150 mL). After evaporation, a 10:1 mixture of Et2θ and hexane (200 mL) was added to the crude ketone. After stirring for 10 h and filtration, the title product was obtained as a solid by filtration (2.40 g).
1H NMR (CD3COCD3): δ 2.45 (3H, s), 4.34 (2H, s), 7.19-7.29 (6H, m), 8.14 (2H, q).
Step 2: Cis, trans-3-chloro-3-(4-fluorophenyl)-2-(4-(methylthio)phenyl)propenal
To a solution of 1-(4-fluorophenyl)-2-(4-(methylthio)phenyl ethanone (2.50 g) in 1,2-dichloroethane (27.0 mL) were introduced the Vilsmeier reagent (Aldrich catalog, 1992-1993) 3.3M (11.6 mL) and DMAP (1.17 g). After a period of 4 h at 80°C, the reaction mixture was extracted with EtOAc and 25% aqueous solution of NH4OAC. After evaporation in vacuo and drying for a few hours, the title product was used as such for the next step.
1H NMR (CD3COCD3): δ 2.40 and 2.48 (3H, 2s), 6.90-7.80 (8H, m), 9.55 (1H, s). Step 3: 5-(4-Fluorophenyl)-4-(4-(methylthio)phenyl)thiophene-2- carboxylic acid methyl ester
To a solution of cis,trans 3-chloro-3-(4-fluorophenyl)-2-(4-(methylthio)phenyl)propenal (3.00 g) in pyridine (12.0 mL) were added methyl thioglycolate (1.16 mL) and Et3N (4.09 mL). The resulting mixture was then heated at 80°C for 2 h. After extraction with EtOAc and washing with 3N HCl, the title product was purified by flash chromatography (30% EtOAc in hexane) (2.00 g).
1H NMR (CD3COCD3): δ 2.48 (3H, s), 3.88 (3H, s), 7.11 (2H, t), 7.21 (4H, s), 7.37 (2H, q), 7.80 (1H, s).
Step 4: 5-(4-Ruorophenyl)-4-(4-(methylsulfinyl)phenyl)thiophene- 2-carboxylic acid methyl ester
To a solution of 5-(4-fluorophenyl)-4-(4-(methylthio)phenyl)thiophene-2-carboxylic acid methyl ester (5.60 g) in CH2CI2 (84.0 mL) at 0°C was added portionwise m-CPBA 50 to 60% (5.39 g). After TLC showed completion (50% EtOAc in hexane), the reaction mixture was extracted with saturated NaHCO3, dried over Na2SO4, filtered and evaporated to dryness to provide the title compound as a white foam (5.00 g).
1H NMR (CD3COCD3): δ 2.75 (3H, s), 3.92 (3H, s), 7.15 (2H, t), 7.40 (2H, q), 7.52 (2H, d), 7.66 (2H, d), 7.90 (1H, s).
Step 5: 4-(4-(Aminosulfonyl)phenyl)-5-(4-fluorophenyl)thiophene- 2-carboxylic acid methyl ester
5-(4-Fluorophenyl)-4-(4-(methylsulfinyl)phenyl)thiophene-2-carboxylic acid methyl ester (0.500 g) was dissolved in TFAA (10.0 mL) and refluxed for 0.5 h. The solvent was then removed in vacuo and the resulting residue was co-evaporated 10 times with a Et3N-MeOH solution (1:1) (100.0 mL) to provide a viscous oil after pumping for a few hours. The oil was dissolved in HO Ac (10.0 mL) and treated at +10°C with Cl2 in HOAc (1.9M) (3.5 mL). After 20 min, the solvent was removed under reduced pressure and after pumping, THF (20.0 mL) was added to the resulting mass of product. After bubbling NH3 through for a few minutes at 0°C, the reaction mixture was stirred for 0.5 h at r.t. After extraction with EtOAc - 25% NH4OAC solution and flash
chromatography (30 to 40% EtOAc in hexane), the title product was obtained as a white solid (0.210 g).
1H NMR (CD3COCD3): δ 3.90 (3H, s), 6.55 (2H, bs), 7.13 (2H, t), 7.40 (2H, q), 7.46 (2H, d), 7.83 (2H, d), 7.90 (1H, s).
Step 6: 3-(4-Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2- hydroxy-2-propyl)thiophene
To 4-(4-aminosulfonyl)phenyl)-5-(4-fluorophenyl)-thiophene-2-carboxylic acid methyl ester (0.460 g) in THF (5.70 mL) at 0°C was added MeMgBr (1.4M) in toluene-THF solution (5.00 mL). The mixture was then stirred at r.t. for a few hours. The reaction was quenched by the addition of 25% NH4OAC solution, extracted with EtOAc and dried over with Na2SO4. The title compound was purified by flash chromatography (40 to 50% EtOAc in hexane) (0.300 g).
1H NMR (CD3COCD3): δ 1.65 (6H, s), 4.52 (1H, s), 6.55 (2H, bs), 7.09 (3H, m), 7.34 (2H, dd), 7.30 (2H, m), 7.43 (2H, d), 7.82 (2H, d).
Analysis calcd. for C19H18FNO3S2
C, 58.31; H, 4.60; N, 3.58
Found: C, 57.94; H, 4.66; N, 3.44
EXAMPLE 2
3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene
Step 1: 4-(4-(Aminosulfonyl)phenyl)-5-(4-fluorophenyl)thiophene- 2-carboxylic acid
To a solution of 4-(4-(aminosulfonyl)phenyl)-5-(4-fluorophenyl)thiophene-2-carboxylic acid methyl ester (Example 1, Step 5) (0.210 g) in THF (2.0 mL) were added MeOH (1.0 mL), NaOH 1N (1.0 mL) and a few drops of NaOH 10N. The resulting mixture was heated at 45 °C for 2 h and the reaction was then partitioned between EtOAc and HCl (3N) to provide the title product as a white solid (0.200 g).
1H NMR (CD3COCD3) δ 6.60 (2H, s), 7.15 (2H, t), 7.35 (2H, q), 7.45 (2H, d), 7.82 (2H, d), 7.87 (1H, s).
Step 2: 3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene
To a solution of 3-(4-(aminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene-2-carboxylic acid (0.280 g) in quinoline (4.0 mL) was added Cu bronze (0.300 g). After 0.5 h at 180°C under nitrogen, the reaction mixture was extracted with EtOAc and HCl 3N, dried over Na2Sθ4 and purified by flash chromatography (30% EtOAc in hexane) to give the title compound as a white solid (0.180 g).
1H NMR (CD3COCD3): δ 6.60 (2H, bs), 7.15 (2H, t), 7.29 (1H, d), 7.35 (2H, q), 7.45 (2H, d), 7.60 (1H, d), 7.83 (2H, d).
Analysis calcd for C16H12FNO2S2
C, 57.65; H, 3.60; N, 4.20
Found: C, 57.62; H, 3.59; N, 4.15 EXAMPLE 3
3-(4-(Aminosulfonyl)phenyl)-2-(4-fluorophenyl)-5-(2-propyl)thiophene
1H NMR (CD3COCD3) δ 1.40 (6H, d), 3.25 (1H, septuplet), 6.58 (2H, bs), 7.05 (1H, s), 7.15 (2H, t), 7.32 (2H, dd), 7.46 (2H, d), 7.80 (2H, d).
Analysis calcd. for C19H18FNO2S2
C, 60.80; H, 4.80; N, 3.73
Found: C, 60.59; H, 4.45; N, 3.60 EXAMPLE 4
3-(4-(Aminosulfonyl)phenyl)-2-cyclohexylthiophene
1H NMR (CD3)2)CO) δ 1.24-1.40 (3H, m), 1.40-1.56 (2H, m), 1.65-1.85 (3H, m), 1.90-2.0 (2H, m), 3.18 (1H, m), 6.58 (2H, bs), 7.05 (1H, d), 7.37 (1H, d), 7.58 (2H, d), 7.97 (2H, d).
EXAMPLE 5
5-(4-Carboxyphenyl)-4-(4-(methylsulfonyl)phenyl)thiophene-2- carboxylic acid
Step 1: 4-(2-(4-(Methylthio)phenyl)-1-oxo-ethyl)benzoic acid
methyl ester
To methyl 4-formylbenzoate (10.30 g) in 1,2-dichloroethane at r.t. were added TMS-CN (6.58 mL) and Znl2 (2.00 g), after 0.5 h at r.t., the solvent was removed in vacuo. To the resulting TMS cyanohyrin (5.00 g) in THF (22.0 mL) at -78°C was added dropwise a solution of LDA 0.87 M in THF (26.2 mL). After a period of 0.5 h, a THF solution (10.0 mL) of 4-(chloromethyl)thioanisole was added dropwise over 0.5 h. The temperature was then brought slowly to -20°C then to 5°C for 2 h and TBAF 1M in THF (50.0 mL) was added. After the addition of 25% aqueous solution of NH4OAC, the reaction mixture was extracted with EtOAc, dried over NASO4, evaporated in vacuo and purified by flash chromatography (20 to 30% EtOAc in hexane) to afford the title compound as a white solid (7.00 g).
Step 2: 4-(1-Oxo-2-(4-(methylsulfonyl)phenyl)ethyl) benzoic acid methyl ester . :
To 7.10 g of 4-(2-(4-(methylthio)phenyl)-1-oxo-ethyl) benzoic acid methyl ester in MeOH (100 mL) was added oxone (21.0 g) in H2O (20.0 mL) at 0°C. After a few hours at r.t., the reaction mixture was extracted with EtOAc and H2O to afford after flash chromatography (50 to 100% EtOAc in hexane), the title product as a white solid (3.20 g). 1H NMR (CD3COCD3) δ 3.10 (3H, s), 3.95 (3H, s), 4.65 (2H, s), 7.60 (2H, d), 7.96 (2H, d), 8.20 (4H, q).
Step 3: Cis,trans 4-(1-Chloro-3-oxo-2-(4-(methylsulfonyl)phenyl)- 1-propenyl)benzoic acid methyl ester
To a solution of 4-(1-oxo-2-((4-methylsulfonyl)phenyl)ethyl) benzoic acid (1.70 g) in 1,2-dichloroethane (15.0 mL) were added the Vilsmeier reagent 3.3 M (6.2 mL) and DMAP (0.624 g). The resulting mixture was heated at 80°C for 4 h. The reaction mixture was then extracted with 25% aqueous solution of NH4OAC and EtOAc. After drying over Na2SO4 and evaporation the title compound was obtained as an oil and used as such for the next step.
Step 4: 5-(4-(Methoxycarbonyl)phenyl)-4-(4-(methylsulfonyl)phenyl)thiophene-2-carboxylic acid methyl ester
Prepared from 4-(1-chloro-3-oxo-2-(4-methylsulfonyl)phenyl)-1-propenyl)benzoic acid methyl ester as for Example 1, Step 3.
1H NMR (CD3COCD3) δ 3.13 (3H, s), 3.85 and 3.92 (6H, 2s), 7.50 (2H, d), 7.55 (2H, d), 7.90 (2H, d), 7.92 (1H, s), 7.92 (2H, d).
Step 5: 5-(4-(Carboxyphenyl)-4-(4-(methylsulfonyl)phenyl)thiophene-2-carboxylic acid
Prepared from 5-(4-(methoxycarbonyI)phenyl)-4-(4- (methyl)sulfonyl)phenyl) thiophene-2-carboxylic acid methyl ester as for
Example 2, Step 1.
1H NMR (CD3COCD3) δ 3.15 (3H, s), 7.50 (2H, d), 7.62 (2H, d), 7.95
(2H, d), 7.98 (1H, s), 8.05 (2H, d).
Analysis calcd. for C19H14O6S2●0.1 H2O
C, 56.46; H, 3.51
Found: C, 56.18; H, 3.51 EXAMPLE 6 4-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)thiazole Step 1: 1-(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone
To 1-(4-Fluorophenyl)-2-(4-(methylthio)phenyl)ethanone of Example 1, Step 1 (17.9 g) in a solution of CH2Cl2-MeOH (272.0 mL/27.0 mL) at 0°C was added MPPM (28.0 g). The cooling bath was then removed and the reaction mixture stirred at r.t. for 1 h. At 0°C, additional MPPM (28.0 g) was added and the reaction mixture kept for 1.5 h at r.t. The insoluble material was filtered followed by evaporation of the solvents, the residue was then extracted with CH2Cl2-NaHCO3. After evaporation in vacuo, the resulting solid was washed with etherhexane (1:1) and filtered to provide the title compound 16.8 g.
1H NMR (CD3COCD3) δ 3.13 (3H, s), 3.58 (2H, s), 7.29 (2H, t), 7.55 (2H, d), 7.88 (2H, d), 8.20 (2H, dd).
Step 2: 2-Bromo-1-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone
To 1 -(4-Fluorophenyl)-2-(4-(methylsulfonyl)phenyl)ethanone (1.00 g) in CH2CI2 containing CHCI3 (1.0 mL) and CCI4 (1.0 mL) was added bromine (0.614 g). After shining light for 1 h, the reaction was quenched with Na2S2O4, extracted with CH2CI2, dried over Na2SO4 and evaporated to yield the title compound which was used as such for the next step (1.10 g).
1H NMR (CD3COCD3) δ 3.10 (3H, s), 7.05 (1H, s), 7.30 (2H, t), 7.87 (2H, d), 7.95 (2H, d), 8.25 (2H, dd).
Step 3: 4-(4-Fluorophenyl)-2-methyl-5-(4-(methylsulfonyl)phenyl)- thiazole
To 2-bromo-1-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)-ethanone (1.10 g) in ethanol (15.0 mL) were added
thioacetamide (0.266 g) and pyridine (0.300 mL). After refluxing for 2 h, the reaction mixture was extracted with EtOAc, 25% NH4OAC and purified by flash chromatography (50% EtOAc in hexane then 90% Et2O in hexane) to yield the title compound (0.320 g).
1H NMR (CD3COCD3) δ 2.72 (3H, s), 3.15 (3H, s), 7.09 (2H, t), 7.52
(2H, dd), 7.60 (2H, d), 7.92 (2H, d).
Analysis calcd. for C17H14FNO2S2
C, 58,78; H, 4.03; N, 4.03
Found: C, 58.71, H, 4.17; N, 3.85
EXAMPLE 7
2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2-cyclopenten-1-one
Step 1: 1-(4-Fluorophenyl)-5-hexen-2-one
To a suspension of 14.6 g (80 mmol) of CdCl2 in 200 mL of ether cooled to 0°C was added 115 mL of 1.3M solution of 3-butene-1-magnesium bromide dropwise. The mixture was refluxed for 1 h and ether was then removed by distillation. Benzene (500 mL) was introduced, followed by a solution of 17.5 g (100 mmol) 4-fluorophenylacetyl chloride. After refluxing for 1 h, the reaction mixture was quenched with 200 mL of saturated aqueous NH4CI, 50 mL of 1N HCl, and extracted with 200 mL of 1:1 hexane/EtOAC. The organic phase was dried over MgSO4 and concentrated. The residue was purified by flash chromatography eluted with 4:1 hexane/EtOAc to give 15 g of the title product.
1H NMR (CDCI3) δ 2.40 (2H, t), 2.53 (2H, t), 3.63 (2H, s), 4.90-4.98 (2H, m), 5.67-5.78 (1H, m), 6.98 (2H, t), 7.13 (2H, m).
Step 2: 1-(4-Fluorophenyl)-5-oxo-2-pentanone
A solution of 14 g of 1-(4-fluorophenyl)-5-hexen-2-one in 200 mL of 3:1 CH2Cl2/MeOH was cooled to -78°C and treated with excess ozone. The resulting mixture was treated with 15 g of
triphenylphosphme and stirred at room temperature for 1 h. The reaction mixture was concentrated and flash chromatographed with 3:1
hexane/EtOAc to give 8 g of the title ketoaldehyde.
1H NMR (CDCl3) δ 2.72 (4H, s), 3.71 (2H, s), 6.99 (2H, t), 7.14 (2H, m), 9.73 (1H, s).
Step 3: 2-(4-Fluorophenyl)-2-cyclopenten-1-one
A solution of 8 g of 1-(4-fluorophenyl)-5-oxo-2-pentanone in 300 mL of MeOH was treated with 2 g of NaOMe. The mixture was stirred for 2 h and then quenched with 5 mL of HO Ac. The solvent was evaporated and the residue purified by flash chromatography, eluting with 3:1 hexane/EtOAc to give 7 g of the title product.
1H NMR (CDCI3) δ 2.57 (2H, m), 2.68 (2H, m), 7.04 (2H, J=8.8 Hz, t), 7.67 (2H, J=8.8, 5.5 Hz, dd), 7.77 (1H, m).
Step 4: 1-(4-(Methylthio)phenyl)-2-(4-fluorophenyl)-2-cyclopenten-1-ol
To a solution of 3.86 g (19 mmol) of 4-bromothioanisole in 90 mL of Et2θ cooled at -78°C, was added 22 mL of 1.7M solution of t-BuLi in pentane (38 mmol) dropwise. The reaction mixture was stirred for 15 min at -78°C and a solution of 2.23 g of 2-(4-Fluorophenyl)-2-cyclopenten-1-one in 10 mL of Et2O was added. After stirring for 15 min at -78°C, the reaction mixture was warmed to 0°C, and quenched with 50 mL of sat. NH4CI. The product was extracted with 100 mL EtOAc, dried over Na2SO4, and purified by flash chromatography, eluted with 4:1 hexane/EtOAc to give 3.4 g of the desired product.
1H NMR (CDCI3) δ 2.12 (1H, s), 2.34 (2H, m), 2.44 (3H, s), 2.45-2.52 (1H, m), 2.56-2.65 (1H, m), 6.37 (1H, m), 6.84 (2H, J=8.7 Hz, t), 7.17 (2H, J=8.3 Hz, d), 7.24-7.33 (4H, m).
Step 5: 2-(4-Fluorophenyl)-3-(4-(methylthio)phenyl)-2-cyclopenten-1-one
To a suspension of PCC (4.5 g, 20.9 mmol) and 10 g of anhydrous 4A molecular sieves in 150 mL of CH2CI2 was added a solution of 2.2 g (7.3 mmol) of 1-(4-(methylthio)phenyl)-2-(4- fluorophenyl)-2-cyclopenten-1-ol in 20 mL CH2CI2. The mixture was stirred for 1 h at r.t. and then diluted with 300 mL of Et2O. After filtration and concentration, the residue was flash chromatographed with 2:1 hexane/EtOAc to give 1.5 g of the title product.
1H NMR (CDCI3) δ 2.45 (3H, s), 2.68 (2H, m), 3.00 (2H, m), 7.02 (2H, J=8.6 Hz, t), 7.11 (2H, J=8.6 Hz, d), 7.15-7.23 (4H, m).
Step 6: 2-(4-Fluorophenyl)-3-(4-(methylsulfonyl)phenyl)-2- cyclopenten-1-one
To a solution of 50 mg (0.17 mmol) of 2-(4-Fluorophenyl)-3-(4-methylthio)phenyl)-2-cyclopenten-1-one in 8 mL of 10:1
CH2Cl2/MeOH was added 124 mg (0.2 mmol) of MPPM. The reaction mixture was stirred at room temperature for 2 h and then diluted with 10 mL of 1:1 hexane/EtOAc. After filtration and concentration, the residue was purified by flash chromatography eluted with 2:1 EtOAc/hexane to give 45 mg of the title product.
1H NMR (acetone-d6) δ 2.67 (2H, m), 3.14 (3H, s), 3.16 (2H, m), 7.05-7.10 (2H, m), 7.20-7.25 (2H, m), 7.63 (2H, d), 7.93 (2H, d).
EXAMPLE 8
4-(4-(Methylsulfonyl)phenyl)-5-(4-fluorophenyl)-isothiazole
To a solution of 338 mg (1 mmol) of cis,trans 3-chloro-3-(4-fluorophenyl)-2-(4-(methylsulfonyl)phenyl)propenal in 5 mL of acetone was added 230 mg (3 mmol) of NH4SCN. The reaction mixture was refluxed for 3 h, and then quenched with 20 mL of saturated NaHCO3. The product was extracted with 100 mL of EtOAc, dried over Na2SO4, concentrated and purified by flash chromatography eluted with 3:2 hexane/EtOAc to give 250 mg of the title product.
1H NMR (CDCI3) δ 8.57 (IH, s), 7.93 (3H, d), 7.50 (2H, d), 7.30 (2H, t), 7.08 (2H, t). EXAMPLE 9 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone Step 1: 2-Bromo-1-(4-(methylsulfonyl)phenyl)ethanone
A solution of 197 g of 4-(Methylthio)acetophenone (ref: JACS, 1952, 74, p. 5475) in 700 mL of MeOH and 3500 mL of CH2CI2 was added 881 g of MMPP over a period of 30 min. After 3 h at room temperature the reaction mixture was filtered and the filtrate was washed with 2L of saturated aqueous solution of NaHCO3 and 1L of brine. The aqueous phase was further extracted with 2L of CH2CI2. The combined extracts was dried over Na2SO4 concentrated to give 240 g of 4-(methylsulfonyl)acetophenone as a white solid.
To a cooled (-5°C) solution of 174 g of 4-(methylsulfonyl)acetophenone in 2.5L of CHCI3 was added 20 mg of AICI3, followed by a solution of 40 mL of Br2 in 300 mL CHCI3. The reaction mixture was then treated with 1.5L of water and the CHCI3 was separated. The aqueous layer was extracted with 1L of EtOAc. The combined extracts was dried over Na2SO4 and concentrated. The crude product was recystalized from 50/50 EtOAc/hexane to give 210 g of 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone as a white solid.
Step 2:
To the product of Step 1 (216 mg) dissolved in acetonitrile (4 mL) was added Et3N (0.26 mL), followed by 4-fluorophenylacetic acid (102 mg). After 1.5 h at room temperature 0.23 mL of DBU was added. The reaction mixture was stirred for another 45 min and then treated with 5 mL of 1N HCl. The product was extracted with EtOAc, dried over Na2SO4 and concentrated. The residue was purified by flash chromatography (40% EtOAc in hexane) to yield 150 mg of the title compound as a solid.
1H NMR (CD3COCD3) δ 3.15 (3H, s), 5.36 (3H, s), 7.18 (2H, J=8.9 Hz, t), 7.46 (2H, m), 7.7 (2H, J=8.65 Hz, d), 7.97 (2H, J=8.68, d). EXAMPLE 10
3-(4-Fluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone 1H NMR (CD3COCD3) δ 5.34 (2H, s), 6.67 (2H, bd), 7.18 (2H, m), 7.46 (2H, m), 7.61 (2H, m), 7.90 (2H, m).
M.P. 187-188°C (d).
EXAMPLE 11 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)furan
Step 1;
Using the product of Example 10, (0.2 g) in THF (5 mL) and toluene (3 mL) was added slowly at -78°C a solution of DIBAL (0.72 mL, 1M in toluene). After 15 min, the solution was warmed up to 0°C for another 15 min. This mixture was then poured into a chilled aqueous solution of sodium potassium tartrate and EtOAc. The organic layer was stirred for 0.5 h with a few crystals of camphor sulfonic acid. This solution was then concentrated and purified by flash chromatography to yield the title compound.
1H NMR (CDCI3) δ 3.1 (3H, s), 7.02 (2H, J=8.9, t), 7.18 (2H, m), 7.4 (2H, J=8.8 Hz, d), 7.58 (1H, s), 7.68 (1H, s), 7.85 (2H, J=8.8 Hz, d).
EXAMPLE 12
5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Step 1: Methyl 2-trimethylsilyloxyisobutyrate
To a solution of 1.2 mL (10.4 mmol) of methyl 2-hydroxyisobutyrate in 50 mL of CH2CI2 were added 1.2 g (17.6 mmol) of imidazole and 2.1 mL (16.6 mmol) of TMSCI. The mixture was stirred at r.t. for 1.5 h and quenched with 20 mL of H2O. The organic layer was dried over MgSO4, concentrated and passed through a short plug of silica gel eluted with 9:1 hexane/EtOAc. Evaporation of solvent afforded 1.27 g of the title compound as a colorless oil.
1H NMR (CD3COCD3) δ 0.08 (9H, s), 1.38 (6H, s), 3.67 (3H, s).
Step 2: 2-Trimethylsilyloxy-4'-(methylthio)isobutyrophenone
A solution of 204 mg (1.0 mmol) of 4-bromothioanisole in 2.5 mL of THF was cooled to -78°C and treated with 0.42 mL of 2.5M n-BuLi solution in hexane. After stirring at -78°C for 1 h, a solution of 380 mg (2.0 mmol) of methyl 2-trimethylsilyloxyisobutyrate in 2 mL of THF was added. The mixture was stirred at -78°C for 2 h and then quenched with NH4OAC buffer. The product was extracted with EtOAc, dried over MgSO4 and concentrated. The residue was purified by flash
chromatography, eluting with 19:1 hexane/EtOAc to give 95 mg of the title product.
1H NMR (CD3COCD3) δ 0.05 (9H, s), 1.52 (6H, s), 2.53 (3H, s), 7.33 (2H, d), 8.12 (2H, d).
Step 3: 2-Hydroxy-4'-(methylthio)isobutyrophenone
To a solution of 40 mg (0.14 mmol) of 2-trimethylsilyloxy-4'-(methylthio)isobutyrophenone in 2 mL THF was added 0.2 mL of 1M n-Bu4NF in THF. The resulting mixture was stirred for 30 min and then quenched with 10 mL of NH4OAC buffer. The product was extracted with EtOAc, dried over MgSO4 and concentrated. The residue was purified by flash chromatography, eluting with 4:1 hexane/EtOAc to give 25 mg of the title product.
1H NMR (CD3COCD3) δ 1.50 (6H, s), 2.54 (3H, s), 4.68 (1H, s), 7.30 (2H, d), 8.15 (2H, d).
Step 4: 2-(4-Fluorophenylacetoxy)-4'-(methylthio)isobutyrophenone
To a solution of 72 mg (0.34 mmol) 2-hydroxy-4'-(methylthio)isobutyrophenone in 1.7 mL of CH2CI2 were added 0.2 mL of pyridine and 140 mg (0.81 mmol) of 4-fluorophenylacetyl chloride. The mixture was stirred at room temperature overnight and then quenched with NH4OAC buffer. The product was extracted with EtOAc, dried over MgSO4 and concentrated. The crude product was purified by flash chromatography eluting with 8:1 hexane/EtOAc to give 95 mg of the title product.
1H NMR (CD3COCD3) δ 1.62 (3H, s), 1.67 (3H, s), 2.48 (3H, s), 3.79 (2H, s), 7.0-7.3 (6H, m), 7.78 (2H, d).
Step 5: 5,5-Dimethyl-3-(4-fluorophenyl-4-(4-(methylthio)phenyl)-2-
(5H)-furanone
To a solution of 95 mg of 2-(4-fluorophenylacetoxy)-4'-(methylthio)-isobutyrophenone in 4 mL of CH2CI2 was added 0.2 mL of 1,8-diazabicyclo(5.4.0)undec-7-ene. The mixture was stirred for 4 h and diluted with NH4OAC buffer. The product was extracted with EtOAc, dried over MgSO4 and concentrated. The residue was purified by flash chromatography, eluting with 20:1 toluene/EtOAc to give 75 mg of the title product.
1H NMR (CD3COCD3) δ 1.58 (6H, s), 2.50 (3H, s), 7.03 (2H, dd), 7.25-7.35 (4H, m), 7.41 (2H, dd).
Step 6: 5,5-Dimethyl-3-(4-fluorophenyl)-4-(4-(methylsulfonyl)- phenyl)-2-(5H)-furanone
To a solution of 81 mg of 5,5-dimethyl-3-(4-fluorophenyl)-4-(4-(methylthio)phenyl)-2-oxo-2H-dihydrofuran in 1.8 mL of CH2CI2 and 0.2 mL of MeOH was added 250 mg of MPPM. The reaction mixture was stirred at room temperature for 1 h and then quenched with aqueous NaHCO3. The product was extracted with EtOAc, dried over MgSO4 and
concentrated. The crude product was purified by flash chromatography eluting with 1:1 hexane/EtOAc to give 73 mg of the title product.
1H NMR (CD3COCD3) δ 1.62 (6H, s), 3.15 (3H, s), 7.02 (2H, dd), 7.40 (2H, dd), 7.65 (2H, d), 8.03 (2H, d).
5,5-Dimethyl-3-(3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone was prepared in an analogous manner (m.p. 172.7ºC). Analysis: Calculated: C, 63.32; H, 4.75;
Found: C, 63.50; H, 4.79; EXAMPLE 13
2-((4-aminosulfonyl)phenyl)-3-(4-fluorophenyl)thiophene 1H NMR (CD3COCD3) δ 6.60 (2H, bs), 7.12 (2H, t), 7.25 (1H, d), 7.35 (2H, m), 7.45 (2H, d), 7.65 (1H, d), 7.85 (2H, d).
Analysis calculated for C16H12FNS2O2
C, 57.65; H, 3.60; N, 4.20
Found: C, 57.55; H, 3.79; N, 4.03
EXAMPLE 14
3-(4-(Trifluoroacetylaminosulfonyl)phenyl)-2-(4-fluorophenyl)thiophene
1H NMR (300 MHz, CD3COCD3) δ 7.15 (2H, t), 7.30 (3H, m), 7.45 (2H, d), 7.65 (1H, d), 7.95 (2H, d).
EXAMPLE 15
3-(2,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H12F2O4S
C, 58.28; H, 3.45; S, 9.15
Found: C, 58.27; H, 3.50; S, 9.27
EXAMPLE 16
3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
To a solution of 3,4-difluorophenylacetic acid (ALDRICH CHIMICAL) (10 g) and 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone (Example 9, Step 1) (17.3 g) in acetonitrile (200 mL) at room temperature was added slowly triethylamine (20.2 mL). After 1 h at room
temperature, the mixture was cooled in an ice bath and treated with 17.4 mL of DBU. After 2 h at 0°C, the mixture was treated with 200 mL of 1N HCl and the product was extracted with EtOAc, dried over Na2SO4 and concentrated. The residue was applied on top of a silica gel plug (sintered glass funnel) eluted with 75% EtOAc/hexane, giving after evaporation of the solvent and swish in ethyl acetate, 10 g of the title compound.
Analysis calculated f or C17H12F2O4S
C, 58.28; H, 3.45; S, 9.15
Found: C, 58.02; H, 3.51; S, 9.35
EXAMPLE 17
3-(2,6-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H12F2O4S
C, 58.28; H, 3.45; S, 9.15
Found: C, 58.18; H, 3.50; S, 9.44 EXAMPLE 18
3-(2,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H12F2O4S
C, 58.28; H, 3.45; S, 9.15
Found: C, 58.89; H, 3.51; S, 9.11
EXAMPLE 19 3-(3,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated f or C17H12F2O4S
C, 58.28; H, 3.45; S, 9.15
Found: C, 58.27; H, 3.62; S, 9.32
EXAMPLE 20 3-(4-Bromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H13BrO4S
C, 51.94; H, 3.33; S, 8.16
Found: C, 51.76; H, 3.42; S, 8.21
EXAMPLE 21
3-(4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
1H NMR (300 MHz, CDCI3) δ 7.93 (2H, d), 7.49 (2H, d), 7.35 (4H, m), 5.16 (2H, s), 3.06 (3H, s).
EXAMPLE 22
3-(4-Methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C18H16O5S
C, 62.78; H, 4.68; S, 9.31
Found: C, 62.75; H, 4.72; S, 9.39 EXAMPLE 23
3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
To a solution of phenylacetic acid (27.4 g, 201 mmol) and 2-bromo-1-(4-(methylsulfonyl)phenyl)ethanone (Example 9, Step 1) (60 g, 216 mmol, 1.075 eq.) in acetonitrile (630 mL) at 25°C was added slowly triethylamine (30.8 mL, 1.1 eq.). The mixture was stirred for 20 min at room temperature and then cooled in an ice bath. DBU (60.1 mL, 3 eq.) was slowly added. After stirring for 20 min in the ice bath, the reaction was complete and the mixture was acidified with 1N HCl (color changes from dark brown to yellow). Then 2.4 L of ice and water were added, stirred for a few minutes, then the precipitate was filtered and rinsed with water (giving 64 g of crude wet product). The solid was dissolved in 750 mL of dichloromethane (dried over MgSO4, filtered) and 300 g of silica gel was added. The solvent was evaporated to near dryness (silica gel a bit sticky) and the residue was apphed on top of a silica gel plug (sintered glass funnel) eluted with 10% EtOAc/CH2Cl2, giving after evaporation of the solvent and swish in ethyl acetate, 36.6 g (58%) of the title compound.
Analysis calculated for C17H14O4S
C, 64.95; H, 4.49; S, 10.20
Found: C, 64.63; H, 4.65; S, 10.44 EXAMPLE 24
3-(2-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H13CIO4S
C, 58.54; H, 3.76; S, 9.19
Found: C, 58.59; H, 3.80; S, 9.37 EXAMPLE 25
3-(2-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H12BrFO4S
C, 49.75; H, 2.93
Found: C, 49.75; H, 3.01 EXAMPLE 26
3-(2-Bromo-4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone 1H NMR (300 MHz, acetone-d6) δ 7.95 (2H, d), 7.85 (1H, d), 7.63 (2H, dd), 7.55 (1H, dd), 7.45 (1H, d), 5.50 (2H, s), 3.15 (3H, s).
EXAMPLE 27 3-(4-Chloro-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
1H NMR (300 MHz, acetone-d6) δ 8.0 (2H, d), 7.70 (2H, d), 7.50-7.30 (3H, m), 5.35 (2h, s), 3.15 (3H, s).
EXAMPLE 28
3-(3-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H12BrFO4S
C, 49.75; H, 2.93
Found: C, 49.44; H, 2.98 EXAMPLE 29 3-(3-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone Analysis calculated for C17H13CIO4S
C, 58.54; H, 3.76
Found: C, 58.29; H, 3.76
EXAMPLE 30
3-(2-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H12CIFO4S
C, 55.67; H, 3.30
Found: C, 55.67; H, 3.26
EXAMPLE 31 3-(2,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated f or C17H12CI2O4S
C, 53.28; H, 3.16; S, 8.37
Found: C, 52.89; H, 3.23; S, 8.58
EXAMPLE 32
3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone Analysis calculated for C17H12CI2O4S
C, 53.28; H, 3.16; S, 8.37
Found: C, 53.07; H, 3.32; S, 8.51 EXAMPLE 33
3-(2,6-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone Analysis calculated for C17H12CI2O4S
C, 53.28; H, 3.16; S, 8.37
Found: C, 52.99; H, 3.22; S, 8.54
EXAMPLE 34
3-(3-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
1H NMR (300 MHz, acetone-d6) d 8.0 (2H, d), 7.70 (2H, d), 7.60 (1H, d), 7.25-7.40 (2H, m), 5.35 (2H, s), 3.15 (3H, s).
EXAMPLE 35
3-(4-Trifluoromethylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
1H NMR (CD3COCD3) δ 8.10 (2H, d), 7.82-7.93 (4H, m), 7.75 (2H, d), 5.55 (2H, s), 3.30 (3H, s). EXAMPLE 36
3-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone Analysis calculated for C18H15FO5S
C, 59.66; H, 4.17
Found: C, 59.92; H, 4.37 EXAMPLE 37
3-(3-Chloro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C18H15CIO5S
C, 57.07; H, 3.99
Found: C, 57.29; H, 4.15 EXAMPLE 38
3-(3-Bromo-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone
Analysis calculated for C18H15BrO5S
C, 51.08; H, 3.57
Found: C, 51.38; H, 3.62
EXAMPLE 39
3-(2-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H13FO4S
C, 61.44; H, 3.94
Found: C, 61.13; H, 3.85
EXAMPLE 40
3-(4-Methylthiophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
1H NMR (300 MHz, acetone-d6) d 8.0 (2H, d), 7.70 (2H, d), 7.35 (2H, d), 7.25 (2H, d), 5.35 (2H, s), 3.15 (3H, s), 2.55 (3H, s). EXAMPLE 41
3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone 1H NMR (300 MHz, CDCl3) d 7.93 (2H, d), 7.49 (2H, d), 7.35 (1H, m), 7.12 (3H, m), 5.18 (2H, s), 3.06 (3H, s).
EXAMPLE 42 3-(2-Chloro-6-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
1H NMR (300 MHz, acetone-d6), d 8.0 (2H, d), 7.70 (2H, d), 7.55-7.65 (1H, m), 7.40 (1H, d), 7.30 (1H, m), 5.60 (2H, s), 3.15 (3H, s).
EXAMPLE 43
3-(3-Bromo-4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C18H15BrO4S
C, 53.08; H, 3.71
Found: C, 53.06; H, 3.83 EXAMPLE 44 3-(4-Bromo-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone Analysis calculated for C17H12BrFO4S
C, 49.65; H, 2.94
Found: C, 49.76; H, 3.00 EXAMPLE 45
3-(3,4-Dibromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone 1H NMR (300 MHz, acetone-d6) δ 8.0 (2H, d), 7.80 (1H, d), 7.75 (3H, m), 7.25 (1H, d), 5.35 (2H, s), 3.15 (sH, s)
EXAMPLE 46 3-(4-Chloro-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H12CIFO4S
C, 55.67; H, 3.30
Found: C, 55.45; H, 3.30
EXAMPLE 47
3-(4-Bromo-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone
Analysis calculated for C17H12BrFO4S
C, 49.66; H, 2.94; S, 7.80
Found: C, 49.79; H, 3.01; S, 7.51
EXAMPLE 48
3-(4-Bromo-2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C17H12BrClO4S
C, 47.74; H, 2.83; S, 7.50
Found: C, 47.92; H, 2.84; S, 7.42 EXAMPLE 49
3-(2-Naphthvl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C21H16O4S
C, 69.22; H, 4.43
Found: C, 69.22; H, 4.46
EXAMPLE 50
3-(7-Ouinolinyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone
Analysis calculated for C20H15NO4S
C, 65.74; H, 4.14; N, 3.83
Found: C, 65.34; H, 4.40; N, 3.80
M.S. (DCI, CH4) calculated for M+, 365
Found for M++ 1, 366
EXAMPLE 51
3-(3,4-Dichlorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone
1H NMR (400 MHz, CD3COCD3) δ 7.92 (2H, dd), 7,64 (3H, dm), 7.60 (1H, dd), 7.32 (1H, dd), 6.70 (1H, bs), 5.38 (2H, s).
EXAMPLE 52 3-(3,4-Difluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone 1H NMR (400 MHz, CD3COCD3) δ 7.92 (2H, dd), 7,64 (2H, dd), 7.30-7.45 (2H, m), 7.22 (1H, m), 6.68 (2H, bs), 5.37 (2H, s). EXAMPLE 53
3-(3-Chloro-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)- furanone
Analysis calculated for C17H14CINO5S
C, 53.76; H, 3.72, N, 3.69
Found: C, 53.32; H, 3.84, N, 3.59
M.S. (DCI, CH4) calculated for M+, 379
Found for M++1, 380
EXAMPLE 54
3-(3-Bromo-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)- furanone
Analysis calculated for C17H14BrNO5S
C, 48.13; H, 3.33, N, 3.30
Found: C, 48.26; H, 3.40, N, 3.28
M.S. (DCI, CH4) calculated for M+, 423
Found for M++1, 424

Claims

WHAT IS CLAIMED IS:
1. A compound selected from the group consisting of:
(a) 3-(2,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(b) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(c) 3-(2,6-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(d) 3-(2,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(e) 3-(3,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(f) 3-(4-Bromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(g) 3-(4-Methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(h) 3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
(i) 3-(2-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(j) 3-(2-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(k) 3-(2-Bromo-4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(l) 3-(4-Chloro-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(m) 3-(3-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(n) 3-(3-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(o) 3-(2-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(p) 3-(2,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone, (q) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(r) 3-(2,6-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-ftιranone,
(s) 3-(3-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(t) 3-(4-Trifluoromethylphenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(u) 3-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
(v) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
(w) 3-(3-Bromo-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
(x) 3-(2-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(y) 3-(4-Methylthiophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(z) 3-(3-Ruorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(aa) 3-(2-Chloro-6-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(bb) 3-(3-Bromo-4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
(cc) 3-(4-Bromo-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(dd) 3-(3 ,4-Dibromophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(ee) 3-(4-Chloro-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(ff) 3-(4-Bromo-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(gg) 3-(4-Bromo-2-chlorophenyl)-4-(4-(methylsulfonyl)-phenyl)- 2-(5H)-furanone, (hh) 3-(2-Naphthyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(ii) 3-(7-Quinolinyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(jj) 3-(3,4-Dichloroρhenyl)-4-(4-(aminosulfonyl)ρhenyl)-2- (2H)-furanone,
(kk) 3-(3,4-Difluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)- furanone,
(ll) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone, and
(mm) 3-(3-Bromo-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone, or a pharmaceutically acceptable salt thereof.
2. A compound selected from the group consisting of: (a) 3-(2,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(b) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(c) 3-(2,6-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(d) 3-(2,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(e) 3-(3,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(f) 3-(4-Bromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(g) 3-(4-Methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(h) 3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5//)-furanone, (i) 3-(2-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(j) 3-(2-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone, (k) 3-(2-Bromo-4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(l) 3-(4-Chloro-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(m) 3-(3-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(n) 3-(3-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(o) 3-(2-Chloro-4rfluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(p) 3-(2,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(q) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(r) 3-(2,6-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(s) 3-(3-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-
2-(5H)-furanone,
(t) 3-(4-Trifluoromethylphenyl)-4~(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(u) 3-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
(v) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
(w) 3-(3-Bromo-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,
(x) 3-(2-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(y) 3-(4-Methylthiophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(z) 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(aa) 3-(2-Chloro-6-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(bb) 3-(3-Bromo-4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, (cc) 3-(4-Bromo-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(dd) 3-(3,4-Dibromophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone,
(ee) 3-(4-Chloro-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(ff) 3-(4-Bromo-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)- 2-(5H)-furanone,
(gg) 3-(4-Bromo-2-chlorophenyl)-4-(4-(methylsulfonyl)-phenyl)- 2-(5H)-furanone,
(hh) 3-(2-Naphthyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(ii) 3-(7-Quinolinyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)- furanone,
(jj) 3-(3,4-Dichlorophenyl)-4-(4-(aminosulfonyl)phenyl)-2- (2H)-furanone,
(kk) 3-(3,4-Difluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)- furanone,
(ll) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone,
(mm) 3-(3-Bromo-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)-2-(2H)-furanone, and
(nn) 5,5-Dimethyl-3-(3-fluorophenyl)-4-(4- methylsulfonylphenyl)-2-(5H)-furanone, or a pharmaceutically acceptable salt thereof.
3. A compound selected from the group consisting of:
Figure imgf000114_0001
4. A compound selected from the group consisting of:
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
5. A compound according to Claim 1 which is
3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2- (5H)-furanone, or
a pharmaceutically acceptable salt thereof.
6. A compound according to Claim 1 which is
3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition for treating an inflammatory disease susceptable to treatment with an non-steroidal anti-inflammatory agent comprising: a non-toxic therapeutically effective amount of a compound according to Claim 1, 2.. 3 , 4 , 5 or 6 and a pharmaceutically acceptable carrier .
8. A pharmaceutical composition for treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1
comprising: a non-toxic therapeutically effective amount of a compound according to Claim 1 , 2 , 3 , 4 , 5 or 6 and a pharmaceutically acceptable carrier.
9. A method of treating an inflammatory disease susceptable to treatment with an non-steroidal anti-inflammatory agent comprising:
administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to Claim 1 and a pharmaceutically acceptable carrier.
10. A method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:
administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to Claim 1.
11. A pharmaceutically acceptable salt of a compound of claim 1, 2, 3, 4, 5, or 6.
12. A compound as defined in claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, for use in the treatment of cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1.
13. A compound as defined in claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, for use in treating an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
14. Use of a compound of claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of an inflammatory disease susceptible to treatment with a non-steroidal anti-inflammatory agent.
15. Use of a compound of claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1.
16. A non-steroidal anti-inflammatory pharmaceutical composition comprising an acceptable non-toxic, anti-inflammatory amount of a compound of claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically
acceptable salt thereof, in association with a
pharmaceutically acceptable carrier.
17. A selective COX-2 inhibitor pharmaceutical composition comprising an acceptable, non-toxic, therapeutically effective amount of a compound of claim 1, 2, 3, 4, 5 or 6, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
PCT/CA1994/000688 1994-01-10 1994-12-19 Phenyl heterocycles as cox-2 inhibitors WO1995018799A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR9408478A BR9408478A (en) 1994-01-10 1994-12-19 Compound pharmaceutical composition processes of treatment of a disease susceptible to treatment with non-steroidal anti-inflammatory agent and treatment of diseases measured by cyclooxygenase, pharmaceutically effective salt and use of a compound
JP7518234A JP2788677B2 (en) 1994-01-10 1994-12-19 Phenyl heterocycle as COX-2 inhibitor
AU12694/95A AU1269495A (en) 1994-01-10 1994-12-19 Phenyl heterocycles as cox-2 inhibitors
EP95903727A EP0739340A1 (en) 1994-01-10 1994-12-19 Phenyl heterocycles as cox-2 inhibitors
NO960393A NO960393L (en) 1994-01-10 1996-01-30 Heterocyclic phenyl compounds as COX-2 inhibitors
BG100350A BG63082B1 (en) 1994-01-10 1996-02-12 Phenyl heterocyclic compounds as cyclooxygenase-2 inhibitors
FI962800A FI108792B (en) 1994-01-10 1996-07-09 Process for the preparation of novel therapeutically useful furanone derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US179,467 1994-01-10
US08/179,467 US5474995A (en) 1993-06-24 1994-01-10 Phenyl heterocycles as cox-2 inhibitors

Publications (1)

Publication Number Publication Date
WO1995018799A1 true WO1995018799A1 (en) 1995-07-13

Family

ID=22656713

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1994/000688 WO1995018799A1 (en) 1994-01-10 1994-12-19 Phenyl heterocycles as cox-2 inhibitors

Country Status (12)

Country Link
EP (1) EP0739340A1 (en)
JP (1) JP2788677B2 (en)
CN (1) CN1143365A (en)
AU (1) AU1269495A (en)
BG (1) BG63082B1 (en)
BR (1) BR9408478A (en)
CA (1) CA2180651A1 (en)
FI (1) FI108792B (en)
HU (1) HUT74986A (en)
NO (1) NO960393L (en)
SG (1) SG43841A1 (en)
WO (1) WO1995018799A1 (en)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011676A1 (en) * 1994-10-12 1996-04-25 Merck Sharp & Dohme Limited Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1998000416A1 (en) * 1996-07-03 1998-01-08 Merck & Co., Inc. Process of preparing phenyl heterocycles useful as cox-2 inhibitors
EP0839034A1 (en) * 1995-07-19 1998-05-06 Merck & Co., Inc. Method of treating colonic adenomas
WO1998041511A1 (en) * 1997-03-14 1998-09-24 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
WO1998046594A1 (en) * 1997-04-11 1998-10-22 Grelan Pharmaceutical Co., Ltd. Pyrazole derivatives and cox inhibitors containing them
WO1998051667A1 (en) * 1997-05-16 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Indole derivatives and mono- and diazaindole derivatives
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
AU715676B2 (en) * 1993-03-12 2000-02-10 Merck Frosst Canada & Co. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US6239173B1 (en) 1993-06-24 2001-05-29 Merck Frosst Canada Inc./Merck Frosst Canada & Co. 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor
WO2002002547A1 (en) * 2000-06-30 2002-01-10 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
WO2003006443A2 (en) * 2001-07-11 2003-01-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg 2- 4-(naphtalin-2-yl)-thiazol-2-ylaminocarbonyl benzoic acid and 2- 4-(naphtalin-2-yl)-pyrimidin-2-ylaminocarbonyl benzoic acid and additional compounds serving as telomerase inhibitors for use in tumor therapy
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US6649649B1 (en) 1995-07-19 2003-11-18 Merck & Co., Inc. Method of treating colonic adenomas
AU775030B2 (en) * 1996-05-17 2004-07-15 Merck Frosst Company Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
US6831097B2 (en) 1997-09-05 2004-12-14 Smithkline Beecham Corporation 2,3-diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
WO2005051935A1 (en) * 2003-11-28 2005-06-09 Il Yang Pharm. Co. Ltd. Method for preparing phenyl heterocycles as cyclooxygenase-2 inhibitor
US6953578B2 (en) * 1996-08-23 2005-10-11 University Of Florida Research Foundation, Inc. Materials and methods for detection and treatment of immune system dysfunctions
DE102004027912A1 (en) * 2004-06-09 2005-12-29 Grünenthal GmbH Substituted cyclopentene compounds
US7087630B2 (en) 2002-06-27 2006-08-08 Nitromed, Inc. Cyclooxygenase 2 selective inhibitors, compositions and methods of use
WO2007109056A2 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP1982711A1 (en) 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
US7745481B2 (en) 1997-12-24 2010-06-29 Daiichi Sankyo Company, Limited Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
EP2302395A1 (en) 2006-06-07 2011-03-30 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2336359A1 (en) 2002-05-09 2011-06-22 The Brigham and Women's Hospital, Inc. 1L1RL-1 as a cardiovascular disease marker and therapeutic target
EP2343553A1 (en) 2004-10-06 2011-07-13 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
WO2011094730A2 (en) 2010-02-01 2011-08-04 The Hospital For Sick Children Remote ischemic conditioning for treatment and reventon of restenosis
WO2011121402A2 (en) 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
EP2541254A2 (en) 2007-04-18 2013-01-02 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2013170186A1 (en) 2012-05-11 2013-11-14 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
US9034585B2 (en) 2005-10-11 2015-05-19 Health Diagnostic Laboratory, Inc. Diabetes-related biomarkers and methods of use thereof
US9040483B2 (en) 2008-06-16 2015-05-26 Biovascular, Inc. Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
WO2015157182A1 (en) 2014-04-07 2015-10-15 Reset Therapeutics, Inc. Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
EP3081214A2 (en) 2003-08-29 2016-10-19 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US9750756B2 (en) 1998-11-30 2017-09-05 Pfizer Inc. Celecoxib compositions
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
US10864255B2 (en) 2000-02-04 2020-12-15 Children's Hospital Medical Center Lipid hydrolysis therapy for atherosclerosis and related diseases
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US10987337B2 (en) 2018-11-21 2021-04-27 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11858909B2 (en) 2021-04-09 2024-01-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388909A2 (en) * 1989-03-22 1990-09-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
WO1991016055A1 (en) * 1990-04-17 1991-10-31 Allergan, Inc. 2(5h)-furanones substituted in the 5 and or in the 4 position, as anti-inflammatory agents
WO1991019708A1 (en) * 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. New thiophene derivatives
WO1994015932A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
WO1995000501A2 (en) * 1993-06-24 1995-01-05 Merck Frosst Canada Inc. Phenyl heterocycles as cyclooxygenase-2 inhibitors
WO1995005376A1 (en) * 1993-08-19 1995-02-23 Warner-Lambert Company Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388909A2 (en) * 1989-03-22 1990-09-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
WO1991016055A1 (en) * 1990-04-17 1991-10-31 Allergan, Inc. 2(5h)-furanones substituted in the 5 and or in the 4 position, as anti-inflammatory agents
WO1991019708A1 (en) * 1990-06-11 1991-12-26 Fujisawa Pharmaceutical Co., Ltd. New thiophene derivatives
WO1994015932A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
WO1995000501A2 (en) * 1993-06-24 1995-01-05 Merck Frosst Canada Inc. Phenyl heterocycles as cyclooxygenase-2 inhibitors
WO1995005376A1 (en) * 1993-08-19 1995-02-23 Warner-Lambert Company Substituted 2(5h)furanone, 2(5h)thiophenone and 2(5h)pyrrolone derivatives, their preparation and their use as endothelin antagonists

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU715676B2 (en) * 1993-03-12 2000-02-10 Merck Frosst Canada & Co. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US6239173B1 (en) 1993-06-24 2001-05-29 Merck Frosst Canada Inc./Merck Frosst Canada & Co. 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor
WO1996011676A1 (en) * 1994-10-12 1996-04-25 Merck Sharp & Dohme Limited Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
EP0839034A4 (en) * 1995-07-19 2002-06-19 Merck & Co Inc Method of treating colonic adenomas
US6649649B1 (en) 1995-07-19 2003-11-18 Merck & Co., Inc. Method of treating colonic adenomas
EP0839034A1 (en) * 1995-07-19 1998-05-06 Merck & Co., Inc. Method of treating colonic adenomas
AU775030B2 (en) * 1996-05-17 2004-07-15 Merck Frosst Company Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
WO1997044028A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
US6063811A (en) * 1996-05-17 2000-05-16 Merck & Co., Inc. Compositions for a once day treatment of cyclooxygenase-2 mediated diseases
CZ297257B6 (en) * 1996-07-03 2006-10-11 Merck And Co., Inc. Process for preparing phenyl heterocyclic derivatives
WO1998000416A1 (en) * 1996-07-03 1998-01-08 Merck & Co., Inc. Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US6953578B2 (en) * 1996-08-23 2005-10-11 University Of Florida Research Foundation, Inc. Materials and methods for detection and treatment of immune system dysfunctions
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
WO1998041511A1 (en) * 1997-03-14 1998-09-24 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
US6136831A (en) * 1997-04-11 2000-10-24 Grelan Pharmaceutical Co., Ltd. Pyrazole derivatives and COX inhibitors containing them
WO1998046594A1 (en) * 1997-04-11 1998-10-22 Grelan Pharmaceutical Co., Ltd. Pyrazole derivatives and cox inhibitors containing them
WO1998051667A1 (en) * 1997-05-16 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Indole derivatives and mono- and diazaindole derivatives
US6831097B2 (en) 1997-09-05 2004-12-14 Smithkline Beecham Corporation 2,3-diaryl-pyrazolo[1,5-B]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
US6861429B2 (en) 1997-09-05 2005-03-01 Smithkline Beecham Corporation 2,3-diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (COX-2) inhibitors
US7745481B2 (en) 1997-12-24 2010-06-29 Daiichi Sankyo Company, Limited Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia
US9750756B2 (en) 1998-11-30 2017-09-05 Pfizer Inc. Celecoxib compositions
US10864255B2 (en) 2000-02-04 2020-12-15 Children's Hospital Medical Center Lipid hydrolysis therapy for atherosclerosis and related diseases
WO2002002547A1 (en) * 2000-06-30 2002-01-10 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
US6465509B2 (en) 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
WO2003006443A3 (en) * 2001-07-11 2003-05-01 Boehringer Ingelheim Pharma 2- 4-(naphtalin-2-yl)-thiazol-2-ylaminocarbonyl benzoic acid and 2- 4-(naphtalin-2-yl)-pyrimidin-2-ylaminocarbonyl benzoic acid and additional compounds serving as telomerase inhibitors for use in tumor therapy
WO2003006443A2 (en) * 2001-07-11 2003-01-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg 2- 4-(naphtalin-2-yl)-thiazol-2-ylaminocarbonyl benzoic acid and 2- 4-(naphtalin-2-yl)-pyrimidin-2-ylaminocarbonyl benzoic acid and additional compounds serving as telomerase inhibitors for use in tumor therapy
EP2336359A1 (en) 2002-05-09 2011-06-22 The Brigham and Women's Hospital, Inc. 1L1RL-1 as a cardiovascular disease marker and therapeutic target
EP3072978A1 (en) 2002-05-09 2016-09-28 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker and therapeutic target
EP3425059A1 (en) 2002-05-09 2019-01-09 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
US7087630B2 (en) 2002-06-27 2006-08-08 Nitromed, Inc. Cyclooxygenase 2 selective inhibitors, compositions and methods of use
US7442802B2 (en) 2002-06-27 2008-10-28 Nitromed, Inc. Cyclooxygenase-2 selective inhibitors, compositions and methods of use
EP3081214A2 (en) 2003-08-29 2016-10-19 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
WO2005051935A1 (en) * 2003-11-28 2005-06-09 Il Yang Pharm. Co. Ltd. Method for preparing phenyl heterocycles as cyclooxygenase-2 inhibitor
US7109214B2 (en) 2004-06-09 2006-09-19 Grunenthal Gmbh Substituted cyclopentene compounds
DE102004027912A1 (en) * 2004-06-09 2005-12-29 Grünenthal GmbH Substituted cyclopentene compounds
EP2343553A1 (en) 2004-10-06 2011-07-13 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
EP1982711A1 (en) 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
EP2808015A1 (en) 2005-05-31 2014-12-03 Mylan Laboratories, Inc Compositions comprising nebivolol
EP2174658A1 (en) 2005-05-31 2010-04-14 Mylan Laboratories, Inc Compositions comprising nebivolol
US9034585B2 (en) 2005-10-11 2015-05-19 Health Diagnostic Laboratory, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007109056A2 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP3279663A1 (en) 2006-03-15 2018-02-07 The Brigham and Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
EP2924440A2 (en) 2006-06-07 2015-09-30 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2302395A1 (en) 2006-06-07 2011-03-30 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
US9689880B2 (en) 2006-06-07 2017-06-27 True Health Ip Llc Markers associated with arteriovascular events and methods of use thereof
US9057736B2 (en) 2006-06-07 2015-06-16 Health Diagnostics Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2891885A2 (en) 2007-04-18 2015-07-08 Health Diagnostic Laboratory, Inc. Diabetes-related biomarkers and methods of use thereof
EP2541254A2 (en) 2007-04-18 2013-01-02 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
US9040483B2 (en) 2008-06-16 2015-05-26 Biovascular, Inc. Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
US9381198B2 (en) 2008-06-16 2016-07-05 Biovascular, Inc. Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
WO2011094730A2 (en) 2010-02-01 2011-08-04 The Hospital For Sick Children Remote ischemic conditioning for treatment and reventon of restenosis
WO2011121402A2 (en) 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
US9265772B2 (en) 2012-05-11 2016-02-23 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
US9775845B2 (en) 2012-05-11 2017-10-03 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
WO2013170186A1 (en) 2012-05-11 2013-11-14 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
US10383880B2 (en) 2012-05-11 2019-08-20 Synchronicity Carbazole-containing sulfonamides as cryptochrome modulators
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US10214507B2 (en) 2014-04-07 2019-02-26 Reset Therapeutics, Inc. Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
US10005759B2 (en) 2014-04-07 2018-06-26 Reset Therapeutics, Inc. Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
US10759777B2 (en) 2014-04-07 2020-09-01 Synchronicity Pharma, Inc. Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
WO2015157182A1 (en) 2014-04-07 2015-10-15 Reset Therapeutics, Inc. Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
EP3939971A1 (en) 2014-04-07 2022-01-19 Synchronicity Pharma, Inc. Carbazole-containing amides, carbamates, and ureas as cryptochrome modulators
WO2020061284A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
US10987337B2 (en) 2018-11-21 2021-04-27 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11559509B2 (en) 2018-11-21 2023-01-24 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11576890B2 (en) 2018-11-21 2023-02-14 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11617735B2 (en) 2018-11-21 2023-04-04 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US11872206B2 (en) 2018-11-21 2024-01-16 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11858909B2 (en) 2021-04-09 2024-01-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Also Published As

Publication number Publication date
CN1143365A (en) 1997-02-19
EP0739340A1 (en) 1996-10-30
NO960393L (en) 1996-07-09
FI962800A0 (en) 1996-07-09
HU9601875D0 (en) 1996-09-30
HUT74986A (en) 1997-03-28
BG100350A (en) 1996-12-31
JP2788677B2 (en) 1998-08-20
JPH09506631A (en) 1997-06-30
AU1269495A (en) 1995-08-01
BR9408478A (en) 1997-08-26
NO960393D0 (en) 1996-01-30
FI108792B (en) 2002-03-28
CA2180651A1 (en) 1995-07-13
BG63082B1 (en) 2001-03-30
FI962800A (en) 1996-09-06
SG43841A1 (en) 1997-11-14

Similar Documents

Publication Publication Date Title
US6239173B1 (en) 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor
WO1995018799A1 (en) Phenyl heterocycles as cox-2 inhibitors
US5840746A (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US6329421B1 (en) Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
EP0788476B1 (en) Stilbene derivatives useful as cyclooxygenase-2 inhibitors
EP0828724B1 (en) Diaryl-5-oxygenated-2-(5h)-furanones as cox-2 inhibitors
US6486194B2 (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
EP0889878A1 (en) Bisarylcyclobutene derivates as cyclooxygenase inhibitors
JP3720634B2 (en) Phenyl heterocycles as cyclooxygenase-2 inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94195045.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU JP KG KR KZ LK LR LT LV MD MG MN NO NZ PL RO RU SI SK TJ TT UA UZ

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2180651

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995903727

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 962800

Country of ref document: FI

Ref document number: 96-01415

Country of ref document: RO

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1995903727

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995903727

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 962800

Country of ref document: FI